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ABSTRACT 
 
Virotherapy, the use of oncolytic properties of viruses for eradication of tumor cells, is an 
attractive strategy for treating cancers resistant to traditional modalities. Adenoviruses can be 
genetically modified to selectively replicate in and destroy tumor cells through exploitation of 
molecular differences between normal and cancer cells.  The lytic life cycle of adenoviruses 
results in oncolysis of infected cells and spreading of virus progeny to surrounding cells for 
local amplification of input dose. Normal cells are spared due to lack of replication. 
Nevertheless, despite excellent preclinical data and proven safety in humans with these 
agents, several obstacles remain. 
 The potency of oncolytic adenoviruses might be limited due to poor transduction of target 
cells. Most adenoviral gene therapy strategies are based on serotype 5 (Ad5), which binds to 
the coxsackie-adenovirus receptor (CAR). However, expression of CAR is frequently low in 
many types of advanced cancers. Lack of CAR can be circumvented by substituting the knob 
domain of the Ad5 fiber with the serotype 3 (Ad3) knob. This allows binding and entry 
through the Ad3 receptor, which is expressed at high levels in most cancers. 
 Clinical trials with early-generation oncolytic viruses have indicated that complete 
elimination of solid tumor masses rarely occurs. A powerful approach for improving the 
efficacy of virotherapy is utilization of oncolytic adenoviruses in combination with 
conventional therapies such as chemotherapeutic agents. We evaluated the use of Ad5/3-Δ24, 
a serotype 3 receptor-targeted oncolytic adenovirus, in combination with gemcitabine or 
epirubicin against ovarian cancer. The combination of these agents showed synergistic cell 
killing in vitro compared with single treatments. Our results also indicate that gemcitabine 
reduces the initial rate of Ad5/3-Δ24 replication without affecting the total amount of virus 
produced. In an orthotopic murine model of peritoneally disseminated ovarian cancer, 
combining Ad5/3-Δ24 with either gemcitabine or epirubicin resulted in greater therapeutic 
benefit than either agent alone, and 60% of mice were cured. However, dose and sequencing 
of the agents were critical for efficacy versus toxicity, as some mice treated with Ad5/3-Δ24 
and gemcitabine succumbed to treatment-related liver damage. 
 Another useful approach for increasing the efficacy of oncolytic agents is to arm viruses 
with therapeutic transgenes such as genes encoding prodrug-converting enzymes. We 
constructed Ad5/3-Δ24-TK-GFP, an infectivity-enhanced oncolytic adenovirus encoding the 
thymidine kinase (TK) – green fluorescent protein (GFP) fusion protein. This novel virus 
replicated efficiently on ovarian cancer cells, which correlated with increased GFP 
expression. Delivery of prodrug ganciclovir (GCV) immediately after infection abrogated 
viral replication, which might have utility as a safety switch mechanism. Oncolytic potency in 
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vitro was enhanced by GCV in one cell line, and the interaction was not dependent on 
scheduling of the treatments. However, in murine models of metastatic ovarian cancer, 
administration of GCV did not add therapeutic benefit to this highly potent oncolytic agent. 
Detection of tumor progression and virus replication with bioluminescence and fluorescence 
imaging provided insight into the in vivo kinetics of oncolysis. 
 For optimizing protocols for upcoming clinical trials, we utilized orthotopic murine 
models of ovarian cancer to analyze the effect of dose and scheduling of intraperitoneally 
delivered Ad5/3-Δ24. Weekly administration of Ad5/3-Δ24 did not significantly enhance 
antitumor efficacy over a single treatment. Our results also demonstrate that even a single 
intraperitoneal injection of only 100 viral particles significantly increased the survival of mice 
compared with untreated animals. 
 Improved knowledge of adenovirus biology has resulted in creation of more effective 
oncolytic agents for cancer gene therapy. However, with more potent therapy regimens an 
increase in unwanted side-effects is also possible. Therefore, inhibiting viral replication when 
necessary would be beneficial. We studied the antiviral activity of chlorpromazine and 
apigenin on adenovirus replication and associated toxicity in vitro in fresh human liver 
samples, normal cells, and ovarian cancer cells. Further, human xenografts in mice were 
utilized to evaluate antitumor efficacy, viral replication, and liver toxicity in vivo. Our data 
suggest that these agents can reduce replication of adenoviruses, which could provide a safety 
switch in case of replication-associated side-effects. 
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REVIEW OF THE LITERATURE 
 
1. Introduction 
 
Cancer is a major health problem, affecting the lives of millions of people globally. An 
estimated 11 million new cases are diagnosed each year, and almost 7 million cancer patients 
will eventually succumb to their disease (Parkin et al. 2005). Although knowledge of 
molecular background, diagnostic methods, and therapies for cancer has improved over the 
past decades, most cancer types continue to have a poor prognosis, and metastatic disease can 
be cured rarely. More efficient approaches and novel tools are therefore needed for the 
treatment of advanced cancer. 
 An increasing understanding of the molecular mechanisms that cause cancer has revealed 
the nature of cancer as a disease of the genes (Hanahan & Weinberg 2000). Human 
carcinogenesis is a multistep process. Most tumors arise from a series of accumulated, 
acquired genetic and epigenetic alterations, typically involving mutations in proto-oncogenes, 
and downregulation of tumor suppressor genes. A logical result of these findings is the idea to 
correct molecular defects to eliminate tumor cells. Alternatively, specific differences between 
malignant and normal cells could be utilized for targeting the antitumor effect to cancer cells.  
 Gene therapy aims at transfer of genes for correction of either genetic or somatic disease 
phenotypes, or for expression of molecules within or near target cells for a therapeutic effect 
(Brand 2009). In recent years, gene therapy has become a widely studied strategy for the 
treatment of diverse diseases. Although gene therapy was initially thought to be more suitable 
for the treatment of hereditary diseases, it has been increasingly exploited for the treatment of 
more complex diseases such as cancer. Cancer gene therapy involves a variety of 
heterogeneous approaches, the common factor of which is the transfer of genes encoding for 
proteins to deliver a therapeutic antitumor effect. Vehicles for gene transfer include both 
nonviral and viral vectors, such as adenovirus, retrovirus, adeno-associated virus, and herpes 
simplex virus (Pereboeva & Curiel 2004). Nonviral gene transfer is most commonly based on 
plasmid DNA, particle bombardment, or cationic liposomes. Viral gene delivery has already 
been optimized by evolution and is therefore generally more effective, while nonviral 
approaches are pharmacologically more attractive. Instead of delivering therapeutic 
transgenes, oncolytic potential of various viruses can be directly utilized for targeted 
destruction of tumor cells in an intriguing strategy called virotherapy. 
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2. Adenoviral cancer gene therapy 
 
Since their first isolation from adenoid tissue in 1953 (Rowe et al. 1953), adenoviruses have 
become one of the most widely studied gene transfer tools in human gene therapy (McConnell 
& Imperiale 2004). At the moment, adenovirus-based systems are the most common vector 
type used in clinical studies worldwide (www.wiley.co.uk/genmed/clinical), representing 25% 
of all gene therapy trials. 
 Adenoviruses possess several features that render them attractive vectors for cancer gene 
therapy (Kanerva & Hemminki 2005). Adenoviruses are capable of efficient gene delivery to 
various cell types, including both dividing and quiescent cells. The molecular biology of 
adenovirus has been well characterized, and its safety has been demonstrated in a large 
number of clinical trials. Adenoviruses are ubiquitous viruses whose native pathogenesis 
typically involves mild upper respiratory tract, ocular, and gastrointestinal infections. 
Adenoviral vectors are stable, easy to manipulate, and production of high titers according to 
current good manufacturing practices (cGMP) is well established. Additionally, adenoviral 
DNA does not integrate into the host genome, resulting in a low risk of mutagenesis. Limited 
duration of viral gene expression may render adenoviruses less desirable for the treatment of 
hereditary diseases, where long-term expression is needed, but is adequate for cancer gene 
therapy, where the purpose is to kill target cells.  
 Adenoviruses are highly immunogenic, which can be advantageous if it leads to an 
antitumor immune response, but can be a disadvantage if the immune response blocks viral 
propagation or leads to toxicity. Variable expression of the adenovirus primary receptor on 
the surface of tumor cells presents another challenge for effective cancer gene therapy. 
Finally, adenoviruses do not inherently possess a mechanism for inactivation. 
   
2.1 Adenovirus 
The adenovirus virion is a nonenveloped icosahedral particle with an outer protein shell 
surrounding an inner nucleoprotein core (Stewart et al. 1991, Stewart et al. 1993). The main 
structural components of the capsid include hexon, penton base, and fiber, along with a 
number of other minor proteins (figure 1). The triangular facets of the capsid are mainly 
composed of hexon trimers (Rux & Burnett 2004). Penton base units are located at each of the 
twelve vertices of the capsid anchoring homotrimeric protruding fibers responsible for the 
virus attachment to the cell surface. The linear, double-stranded 38-kb DNA genome is 
packaged within the capsid and is associated with histon-like core proteins.   
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Figure 1. Structure of the adenovirus particle (Volpers & Kochanek 2004). 
 
Over 50 different serotypes of human adenovirus have been classified into six subgroups (A-
F) based on sequence homology and their ability to agglutinate red blood cells (McConnell & 
Imperiale 2004). The most commonly used vector for gene therapy, adenovirus serotype 5 
(Ad5), belongs to subgroup C. Infection of Ad5 (figure 2) starts by high-affinity binding of 
the fiber globular knob domain to the cell surface coxsackie-adenovirus receptor (CAR), a 
type I transmembrane protein of the immunoglobulin superfamily (Bergelson et al. 1997). 
Members of all subgroups, except group B adenoviruses, utilize CAR as a primary receptor 
(Roelvink et al. 1998).  Recently, members of subgroup B have been shown to bind either 
CD46, CD80/86, unidentified glycoprotein “receptor X”, or combinations of these receptors 
(Gaggar et al. 2003, Short et al. 2004, Sirena et al. 2004, Marttila et al. 2005, Tuve et al. 
2006). Sialic acid is also involved in the uptake of some subgroup D adenoviruses (Wu et al. 
2003). In addition, heparan sulfate proteoglycans (HSPGs) have been suggested to promote 
adenovirus virion attachment to certain cell types, including liver cells, via the putative 
lysine-lysine-threonine-lysine (KKTK) motif on the fiber shaft (Dechecchi et al. 2001, Smith 
et al. 2003). However, recent studies argue against the role of the KKTK motif in determining 
infectivity towards hepatic cells in vivo (Shayakhmetov et al. 2005, Parker et al. 2006, Di 
Paolo et al. 2007). Further, mutation of the KKTK motif seems to affect more than just HSPG 
binding and might interfere with the correct folding of the fiber (Bayo-Puxan et al. 2006, 
Kritz et al. 2007). 
  Initial attachment is followed by internalization of the virus, mediated by secondary 
interaction of a penton base arginine-glycine-aspartic acid (RGD) motif and cellular αvβ 
integrins, which triggers endocytosis of the virion via clathrin-coated pits (Wickham et al. 
1993, Stewart et al. 1997). In the endosome, the virus is disassembled followed by endosomal 
lysis (Greber et al. 1993). Thereafter, viral DNA is transported to the nucleus through a 
microtubule-mediated process, and viral genes are expressed (Leopold et al. 2000).  
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Figure 2. Schematic illustration of the Ad5 infection pathway. Initial attachment is mediated by coxsackie-
adenovirus receptor (CAR), followed by an interaction with cellular integrins resulting in internalization of the 
virus via clathrin-mediated endocytosis. In the endosomes, viral genome is released and transported to nucleus 
for DNA replication (Kanerva & Hemminki 2005). 
 
The adenoviral genome can be divided into immediate early (E1A), early (E1B, E2, E3, E4), 
intermediate (IX, IVa2), and late (L1-L5) genes (figure 3). Transcription of these genes can be 
defined as a two-phase event, early and late, occurring before and after virus DNA replication 
(Russell 2000). The first transcription unit to be expressed is E1A, whose products function to 
transactivate other early genes and to induce the cell to enter the S phase for replication of the 
viral genome (Berk 1986). The early gene region encodes mainly regulatory proteins 
necessary for viral replication, alteration of the host cell cycle, prevention of apoptosis, and 
interference with the host cell defense mechanisms (Russell 2000). After DNA replication, 
intermediate genes are produced, followed by expression of late genes driven by the major 
late promoter (MLP). These genes encode structural components of the virus as well as 
proteins involved in virion assembly. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Map of the Ad5 genome and transcription units. Promoters are depicted by arrowheads; early (E) and 
late (L) genes are depicted by thin and heavy arrows, respectively. Arrows indicate the direction of transcription. 
MLP; major late promoter (Volpers & Kochanek 2004). 
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2.2 Targeting adenoviral vectors to cancer cells 
The key to successful cancer gene therapy lies in the efficient delivery of transgenes 
specifically to target cells. As viral tropism is mainly determined by the degree of receptor 
expression, cells producing low levels of CAR are refractory to Ad5 infection and gene 
transfer (Kim et al. 2002). Although CAR is ubiquitously expressed on a broad range of 
normal epithelial cells, production of CAR is frequently low in many tumor types, including 
ovarian cancer (Dmitriev et al. 1998, Miller et al. 1998, Cripe et al. 2001, Kanerva et al. 
2002b, Shayakhmetov et al. 2002). Increased CAR expression appears to have a growth 
inhibitory effect on some cancer cell lines, while loss of CAR expression correlates with 
tumor progression and advanced disease (Okegawa et al. 2001). CAR is localized in tight 
junctions, which suggests a role on cell adhesion, and its expression may be cell cycle-
dependent (Cohen et al. 2001, Seidman et al. 2001). Various strategies have been evaluated to 
modify adenovirus tropism in order to circumvent CAR deficiency, to enhance transduction 
of cancer cells, and to reduce infectivity of normal tissues (Saukkonen & Hemminki 2004, 
Glasgow et al. 2006, Campos & Barry 2007).  
       
2.2.1 Transductional targeting via adapter molecules 
Transductional targeting can be achieved by utilizing bispecific adapter molecules that block 
the interaction with CAR and redirect the virus to a novel receptor. Various molecules have 
been evaluated to physically bridge the vector to cell surface receptors: 1) bispecific 
antibodies, 2) chemical conjugates between antibody fragments (Fab) and cell-specific 
ligands, 3) Fab-antibody conjugates using antibodies against target cell receptors, 4) Fab-
peptide ligand conjugates, and 5) recombinant fusion proteins that incorporate Fabs and 
peptide ligands.  
 The first demonstration of adapter-based retargeting was carried out by utilizing 
bispecific conjugate consisting of an anti-fiber neutralizing Fab chemically linked to folate 
(Douglas et al. 1996). This approach resulted in CAR-independent uptake of virus via folate 
receptors highly expressed on the surface of a variety of malignant cells. Several other Fab-
ligand conjugates targeted against, for instance, basic fibroblast growth factor (FGF2) 
receptor (Goldman et al. 1997, Rancourt et al. 1998, Gu et al. 1999), epidermal growth factor 
(EGF) receptor (Miller et al. 1998), epithelial cellular adhesion molecule (Ep-CAM) (Haisma 
et al. 1999, Heideman et al. 2001), tumor-associated glycoprotein 72 (TAG-72) (Kelly et al. 
2000), or CD40 (Tillman et al. 1999, Hakkarainen et al. 2003) have been linked to an Ad5 
fiber for enhanced transduction of cancer cells. Reynolds et al. (2000) succeeded in targeting 
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pulmonary endothelial cells in vivo after systemic administration of a virus modified with 
bispecific antibody against Ad5 fiber and angiotensin-converting enzyme (ACE).  
 An alternative approach to chemical conjugates utilized a single recombinant fusion 
molecule formed by a truncated, soluble form of CAR (sCAR) fused to either anti-CD40 
antibody or EGF (Dmitriev et al. 2000, Hemminki et al. 2001b, Pereboev et al. 2002). To 
further increase the stability of the complex, a trimeric sCAR-fibritin-anti-erbB2 single-chain 
antibody molecule was created for targeting c-erbB2-positive cancer cells (Kashentseva et al. 
2002). Recently, sCAR was fused to a single-chain antibody directed against 
carcinoembryonic antigen (CEA), resulting in increased gene expression in CEA-positive 
lung cells and reduced liver transduction after systemic delivery in mice (Everts et al. 2005, 
Li et al. 2007).   
 
2.2.2 Transductional targeting via genetic manipulation 
Another strategy for transductional targeting involves genetic manipulation of viral capsid 
proteins. Based on native adenovirus receptor recognition, the development of genetically 
targeted viruses has mainly concentrated on structural modifications of the fiber knob domain 
including: 1) peptide incorporation into the fiber knob, 2) pseudotyping of the fiber, and 3) 
deknobbing of the fiber. In addition, other capsid locales have recently been evaluated for 
inclusion of targeting moieties.  
 Structural analysis of the major capsid proteins has facilitated the genetic incorporation of 
foreign peptides into exposed regions of the adenovirus capsid. Initial studies have 
demonstrated that short peptides can be inserted into the C terminus and HI loop of the fiber 
knob (Wickham et al. 1996a, Dmitriev et al. 1998, Krasnykh et al. 1998), the RGD-containing 
loop of the penton base (Wickham et al. 1996b), the hypervariable region 5 (HVR5) loop of 
the hexon (Crompton et al. 1994, Wu et al. 2005), and the C terminus of protein IX (Dmitriev 
et al. 2002). Adenoviruses with an integrin-binding RGD motif or heparan sulphate-binding 
polylysine residues (pK7) incorporated into the C terminus of the fiber knob have yielded 
positive results in vitro and in vivo, but insertion of larger peptides may result in inefficient 
packaging of the virion (Wickham et al. 1997, Wu et al. 2002). The HI loop can tolerate 
peptide insertions of up to 100 amino acids, with variable effects on virion integrity. 
Incorporation of RGD-4C peptide into the HI loop enhanced the transduction of Ad5 to a 
wide range of tumor cells, including ovarian cancer cells (Dmitriev et al. 1998, Vanderkwaak 
et al. 1999, Hemminki et al. 2001a, Hemminki et al. 2002b). Wu et al. (2002) created a double 
modified virus with a RGD motif in the HI loop and a pK7 motif in the C terminus. This virus 
resulted in enhanced infectivity towards ovarian cancer cells compared with viruses carrying a 
single targeting moiety (Wu et al. 2004). Other peptides have been incorporated into the HI 
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loop as well (Mizuguchi et al. 2001, Nicklin et al. 2001). In addition, the RGD motif has been 
successfully inserted into HRV5 of the hexon (Vigne et al. 1999) and into the C terminus of 
protein IX (Vellinga et al. 2004). Recently, the C terminus of protein IX has gained attention 
due to its ability to display large polypeptides and proteins on the surface of the virion. 
Instead of targeting, incorporation of large reporter enzymes allows noninvasive monitoring 
of viral functions (Le et al. 2004, Li et al. 2005, Matthews et al. 2006). However, most of the 
strategies utilizing direct ligand incorporation have resulted in vectors with expanded, rather 
than restricted, tropism. Incorporation of cell binding ligands isolated by phage display 
technique, or inserting mutations that ablate CAR binding could produce vectors with more 
specificity towards target cells (Nicklin et al. 2001, Nicklin et al. 2004, Work et al. 2004a).  
  Adenovirus fiber pseudotyping is a strategy that exploits the natural diversity of the 
adenovirus family. Genetic replacement of the entire fiber or the knob region of Ad5 with its 
structural counterpart from another serotype results in CAR-independent transduction of a 
variety of cell types (Havenga et al. 2002). Most of the studies have evaluated Ad5- or Ad2-
based vectors with the fiber or knob derived from subgroup B or D adenoviruses. Adenovirus 
serotype 3 (Ad3) is a member of subgroup B and therefore recognizes a different receptor 
than Ad5 (Stevenson et al. 1995). Substitution of the knob domain of Ad5 with the 
corresponding domain of Ad3 allows binding and entry through the Ad3 receptor, which is 
expressed to a high degree on tumor cells (Krasnykh et al. 1996, Stevenson et al. 1997, 
Kanerva et al. 2002a). Ad5/3 chimeric virus displayed enhanced infectivity towards ovarian 
cancer cells and was able to partially avoid the effect of pre-existing neutralizing anti-Ad5 
antibodies (Kanerva et al. 2002a, Kanerva et al. 2002b). Further, the biodistribution, liver 
toxicity, and blood clearance rates were comparable with wild-type Ad5 virus, suggesting 
excellent preclinical safety of this approach. Various pseudotyped adenoviruses, including 
fiber regions from serotypes Ad7 (Gall et al. 1996), Ad11 (Stecher et al. 2001), Ad16 
(Goossens et al. 2001, Havenga et al. 2001), Ad17 (Chillon et al. 1999, Zabner et al. 1999), 
Ad35 (Shayakhmetov et al. 2000, Rea et al. 2001, Mizuguchi & Hayakawa 2002), and several 
others (Denby et al. 2004, Parker et al. 2007), have been constructed for improved 
transduction of a broad range of clinically relevant cell types. Moreover, this approach has 
exploited fiber elements from nonhuman viruses (Glasgow et al. 2004, Stoff-Khalili et al. 
2005, Nakayama et al. 2006) and the fiber-like σ1 reovirus attachment protein (Mercier et al. 
2004, Tsuruta et al. 2005, Tsuruta et al. 2007). 
 Finally, deletion of the entire knob region results in knobless fibers and total ablation of 
CAR binding. Addition of targeting ligand to such fibers allows more specific recognition of 
target cells. However, trimerization of the fiber protein, which is required for proper function 
of the fiber, is normally mediated by the knob domain. This problem has been solved by 
utilizing external trimerization signals, such as MoMuLV envelope glycoprotein trimerization 
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motif (van Beusechem et al. 2000), a neck region peptide of human lung surfactant protein D 
(Magnusson et al. 2001), or the foldon domain of bacteriophage T4 fibritin protein (Krasnykh 
et al. 2001).  
 
2.2.3 Transcriptional targeting 
Instead of changing tropism of adenoviruses, expression of viral genes or transgenes can be 
restricted to tumor cells by placing the desired gene under the control of tumor- or tissue-
specific promoter (TSP). The gene is therefore expressed selectively in cells with high 
promoter activity.  Additionally, promoters induced by the unique tumor environment, 
treatment, or certain chemicals can be used to regulate gene expression.  
 Several TSPs have been explored in order to limit the expression of transgenes 
specifically to ovarian cancer cells (Casado et al. 2001b, Saukkonen & Hemminki 2004). 
Leukocyte plastin (L-plastin) is expressed during tumorigenesis, especially in the context of 
gynecological cancers arising from estrogen-dependent tissues (Lin et al. 1993). 
Transcriptional control of adenovirus with the L-plastin promoter (LP-P) induced expression 
of a reporter gene in ovarian cancer cell lines and ascites samples, but little activity was seen 
in normal human tissues (Chung et al. 1999). In another study, suppression of ovarian tumor 
growth in mice was achieved when the suicide gene was placed under the control of LP-P 
(Peng et al. 2001).  
 Expression of cyclooxygenase-2 (cox-2) is normally low in most tissues, but can be 
highly induced in response to cell activation by hormones, proinflammatory cytokines, 
growth factors, and tumor promoters (Saukkonen et al. 2003). The cox-2 promoter has been 
investigated in the context of ovarian cancer, with promising results (Casado et al. 2001a). 
 The secretory leukoprotease inhibitor (SLPI) gene is expressed in several different 
carcinomas, while its expression in normal organs is low (Abe et al. 1997). High activity of 
the SLPI promoter was demonstrated in ovarian cancer cell lines, in primary ovarian tumor 
cells isolated from patient samples, and in an orthotopic murine model of ovarian cancer 
(Barker et al. 2003a). Intraperitoneal (i.p.) delivery of adenovirus armed with the SLPI-driven 
suicide gene resulted in increased survival of tumor-bearing mice after administration of a 
prodrug. 
 Various other TSPs have also been evaluated for the selectivity towards ovarian cancer 
cells, including CXC chemokine receptor 4 (CXCR4) (Zhu et al. 2004), DF3/MUC1 (Tai et 
al. 1999), mesothelin (Breidenbach et al. 2005), midkine (MK) (Casado et al. 2001a), and 
ovarian-specific promoter-1 (OSP1) (Bao et al. 2002). 
 Although TSPs have the potential to increase specificity and decrease toxicity of 
adenoviral gene therapy, vectors targeted with TSPs are still dependent on CAR for cell entry. 
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Therefore, viruses combining both transductional and transcriptional targeting moieties have 
been developed (Reynolds et al. 2001, Barker et al. 2003b, Work et al. 2004b). 
   
2.2.4 Obstacles to systemic targeting 
Despite advances in vector retargeting, several obstacles that inhibit the systemic delivery of 
adenoviruses remain. Although mechanisms of adenovirus attachment and uptake are 
relatively well understood in vitro, less is known about mechanisms governing in vivo 
infection. Studies have shown that CAR expression levels do not correlate with the virus 
biodistribution, and ablation of CAR binding does not have a significant impact on infectivity 
in vivo (Fechner et al. 1999, Alemany & Curiel 2001).  
 The majority of intravascularly administered adenovirus is rapidly cleared from the blood 
circulation, accumulating in liver tissues (Alemany et al. 2000). Uptake of vector particles by 
Kupffer cells, resident macrophages in the liver, decreases the amount of virus available for 
therapeutic purposes. Therefore, high viral doses are required for effective transduction of 
target tissues, which can result in acute toxicity and compromise the safety of the patient. 
Recently, several blood factors were identified that promote CAR-independent infection of 
murine hepatocytes (Shayakhmetov et al. 2005, Parker et al. 2006, Baker et al. 2007). 
Intravascularly delivered adenovirus interacts directly with vitamin K-dependent coagulation 
zymogens (FVII, FIX, FX, protein C) and complement C4-binding protein (C4BP), which 
form a bridge between virus particles and hepatic HSPGs or low-density lipoprotein receptor-
related protein (LRP). Recent studies suggest that adenovirus binding to FIX occurs via Ad5 
hexon protein instead of the fiber knob (Kalyuzhniy et al. 2008, Waddington et al. 2008). 
Besides plasma proteins, adenovirus can also have direct interactions with host blood cells, 
preventing access of the vector to target cells (Cotter et al. 2005, Lyons et al. 2006, Stone et 
al. 2007). 
 In addition to sequestration by nontarget tissues, systemic delivery of adenovirus triggers 
innate immunity, including induction of cytokines, inflammation, transient liver toxicity, and 
thrombocytopenia (Muruve 2004). These responses represent a major barrier for clinical gene 
therapy and result in part from the uptake of vector particles by Kupffer cells. Initial 
responses are triggered by the actual viral capsids, which are independent of the transcription 
of viral genes. Innate host responses are followed by activation of the adaptive immune 
system and production of neutralizing antibodies (NAbs) (Bessis et al. 2004). Pre-existing 
NAbs derived from previous exposure to adenovirus through either natural infection or 
administration of the vector can significantly reduce the effect of therapy. 
 Furthermore, viral spread in the solid tumor mass can be limited by physical barriers, 
including extracellular matrix (ECM) and connective tissue (Harrison et al. 2001, Cheng et al. 
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2007a). In addition to physical limitations, solid tumors contain physiologically different sub-
compartments, such as necrotic, hypoxic, or hyperbaric regions, which can restrict the 
dissemination of the virus.  
 
3. Oncolytic virotherapy 
 
Due to safety concerns, gene therapy approaches have traditionally been based on viruses that 
are unable to replicate in infected cells. Although replication-deficient viruses expressing 
therapeutic transgenes have provided high preclinical efficacy and good clinical safety data, 
trials have demonstrated that the utility of these agents may be limited when faced with 
advanced and wide-spread disease. Viruses that replicate and spread specifically inside the 
tumor have been suggested as a way of improving penetration of and dissemination within 
solid tumor masses (Liu & Kirn 2008). Oncolytic viruses used in various cancer gene therapy 
approaches take advantage of tumor-specific changes that allow preferential replication of the 
virus in target cells (figure 4). The viral replication cycle causes oncolysis of the cell, 
resulting in the release of newly generated virions and subsequent infection of neighboring 
cells. Normal tissue is spared due to lack of replication. Thus, the antitumor effect is delivered 
by the actual replication of the virus. Therefore, a transgene is not necessarily required, but 
can be used for additional efficacy. The viral replication cycle allows dramatic local 
amplification of the input dose, and in theory, the oncolytic process continues as long as 
target cells persist. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Principle of oncolytic virotherapy. Viral infection of cancer cells results in replication, oncolysis and 
release of virions to surrounding cells. Normal cells are spared due to lack of replication. 
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Various approaches exist for achieving selective viral replication in tumor cells. As the 
cellular changes induced by viral infection are often similar to changes acquired during tumor 
development, it is not surprising that some viruses, such as measles and vesicular stomatitis 
virus, have inherent selectivity for cancer cells. However, many popular oncolytic viruses, 
including adenovirus, are genetically modified to replicate specifically in tumor cells 
(Kanerva & Hemminki 2005). One way to restrict replication of adenoviruses to malignant 
tissues is to limit the expression of the viral E1A gene product to cancer cells with TSPs. 
Another strategy involves engineering deletions in viral genes critical for efficient replication 
in normal cells but not in cancer cells.  
 
3.1 Type I oncolytic adenoviruses 
With type I oncolytic adenoviruses, tumor-specific replication is achieved by introduction of 
loss-of-function mutations to the virus genome that require specific cellular factors to 
compensate for the effects of these mutations. Most approaches are based on deletions in E1A 
or E1B adenoviral genes, resulting in mutant proteins unable to bind the cellular proteins 
necessary for viral replication in normal cells, but not in cancer cells (Kanerva & Hemminki 
2005).  
 The first and most widely studied oncolytic adenovirus, ONYX-015 (dl1520), carries two 
deletions in the gene coding for the E1B-55 kD protein (Bischoff et al. 1996). One purpose of 
this protein is binding and inactivation of tumor suppressor protein p53 in infected cells, for 
induction of the S phase, which is required for effective virus replication (figure 5). Thus, this 
virus may have selectivity for cells with an aberrant p53-p14ARF pathway, a common feature 
of human tumors (Hollstein et al. 1991). Initial studies suggested that this agent replicates 
selectively in cancer cells lacking functional p53 (Bischoff et al. 1996, Heise et al. 1997, 
Heise et al. 1999, Rogulski et al. 2000a). However, contradicting studies have suggested that 
cells with functional p53 also support ONYX-015 replication (Goodrum & Ornelles 1998, 
Rothmann et al. 1998). Clearly, factors independent of p53 play critical roles in determining 
the sensitivity of cells to ONYX-015. Loss of function of p14ARF, which normally stabilizes 
p53, can result in inactivation of p53 (Ries et al. 2000). Adenoviral proteins other than E1B-
55 kD, including E4orf6, E1B-19 kD, and E1A, have effects on p53 function (Dobner et al. 
1996). Further, the functions of E1B-55 kD are not limited to p53 binding, but include also 
mRNA transport (Yew et al. 1994), and therefore, the virus replicates inefficiently compared 
with the wild-type adenovirus. Nevertheless, taken together, ONYX-015 data seem to suggest 
more effective replication in tumor cells than in normal cells (Kirn 2001).  
 Ad5-Δ24 and dl922-947 are closely related viruses that carry a 24-bp deletion in constant 
region 2 (CR2) of the E1A gene (Fueyo et al. 2000, Heise et al. 2000a). This domain of the 
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E1A protein is responsible for binding of the retinoblastoma protein (pRb) for induction of the 
S phase and DNA replication (Whyte et al. 1988, Whyte et al. 1989). In normal cells, pRb 
acts as a tumor suppressor by inhibiting cell cycle progression via binding to E2F, a 
transcriptional activator that promotes expression of genes necessary for driving the cell into 
S phase (Nevins 1992). Adenoviral E1A binds to pRb and releases repression of E2F, 
allowing it to activate its target genes. However, viruses with CR2 deletion in E1A are unable 
to bind pRb and have reduced ability to overcome the G1/S checkpoint. Therefore, they 
replicate selectively in cells deficient in the pRb-p16 pathway, including most cancer cells 
(Sherr 1996, D'Andrilli et al. 2004). These viral agents are promising anticancer agents, as 
they are not attenuated in comparison with wild-type viruses, and some reports suggest that 
they may be even more oncolytic than wild-type viruses in tumor cells (Heise et al. 2000a). 
However, safety of this approach has not yet been demonstrated in currently ongoing human 
trials (www.wiley.co.uk/genmed/clinical).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Intervention by viral proteins leads to loss of cell cycle control. Tumor suppressor protein p53 is 
upregulated and activated upon stress signals such as DNA damage or viral infection. p53 can act as a 
transcription factor to activate expression of genes that induce apoptosis or cell cycle arrest. Adenoviral E1B-55 
kD binds to and inactivates p53 leading to progression into the S phase. Retinoblastoma protein (pRb) regulates 
the G1/S cell cycle checkpoint. pRb exerts its effects by binding to and inhibiting transcription factor E2F, which 
induces expression of genes needed for DNA synthesis. Adenoviral E1A binds to pRb releasing repression of 
E2F, allowing it to activate its target genes and leading to progression into the S phase. However, targeted 
deletions in E1B-55 kD or E1A result in mutant proteins unable to bind p53 or pRb, respectively. Therefore, 
modified viruses replicate only in cells deficient in these pathways, including most cancer cells (Everts & van 
der Poel 2005).  
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3.2 Type II oncolytic adenoviruses 
With type II oncolytic adenoviruses, TSPs replace endogenous viral promoters, restricting 
viral replication to target tissues expressing the TSP. Usually, the promoter is placed to 
control E1A, but alternatively, or in addition, other early genes can also be regulated. Various 
TSPs have been used to limit viral replication to desired tissues, including alpha-fetoprotein 
(Hallenbeck et al. 1999, Li et al. 2001), cox-2 (Yamamoto et al. 2003, Kanerva et al. 2004), 
CXCR4 (Rocconi et al. 2007), DF3/MUC1 (Kurihara et al. 2000), E2F (Tsukuda et al. 2002, 
Jakubczak et al. 2003, Ryan et al. 2004), human telomerase reverse transcriptase (hTERT) 
(Uchino et al. 2005), IAI.3B (Hamada et al. 2003), mesothelin (Tsuruta et al. 2008), MK (Ono 
et al. 2005), prostate-specific antigen (PSA) (Rodriguez et al. 1997, Yu et al. 1999), SLPI 
(Maemondo et al. 2004, Rein et al. 2005), survivin (Zhu et al. 2005), and tyrosinase 
(Nettelbeck et al. 2002, Banerjee et al. 2004, Ulasov et al. 2007). 
 Oncolytic adenoviruses combining both type I and type II strategies have been 
constructed (Doloff et al. 2008). Such double-control of viral replication is advantageous over 
a single-control approach because specificity may be gained without loss of efficacy. 
 
3.3 Clinical trials with oncolytic adenoviruses 
The first cancer trials with replicating adenoviruses were done already in the 1950s (Smith et 
al. 1956). Ten different serotypes of wild-type adenoviruses were applied intratumorally (i.t.), 
intra-arterially (i.a.), by both routes, or intravenously (i.v.) into patients with cervical 
carcinoma. No significant toxicity was reported. A “marked to moderate local tumor 
response” was described in over half of the patients. However, systemic responses were not 
detected, and all patients eventually had tumor progression. Although these clinical studies 
were not performed according to current clinical research standards, they suggest that 
oncolytic adenoviruses can be safely administered to humans, and that viruses can replicate in 
tumors for therapeutic effect.  
 The safety and antitumor efficacy of ONYX-015 has been tested in numerous clinical 
trials with various tumor types and several routes of administration, with and without 
concomitant conventional treatments (table 1). The goal has been to sequentially increase 
systemic exposure to the virus after safety with localized delivery has been shown. Following 
demonstration of safety and biological activity by the i.t. route, trials were initiated to study 
intracavitary, i.a., and eventually i.v. administration of ONYX-015 (Kirn 2001). In summary, 
ONYX-015 has been well tolerated even at the highest doses administered by any route of 
administration. The lack of clinically significant toxicity has been remarkable. Flu-like 
symptoms have been the most common toxicities, and have been more frequent in patients 
receiving intravascular treatment. Unfortunately, single-agent antitumoral activity has mostly 
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been limited to head and neck cancers (Nemunaitis et al. 2000, Nemunaitis et al. 2001b). 
However, favorable and potentially synergistic interaction with chemotherapy has been 
discovered in multiple tumor types, and by multiple routes of administration (Khuri et al. 
2000, Lamont et al. 2000, Reid et al. 2001, Reid et al. 2002, Hecht et al. 2003, Galanis et al. 
2005). 
 Recently, i.t. injection of H101, an oncolytic adenovirus closely related to ONYX-015, 
was evaluated in a phase III trial against squamous cell carcinoma of the head and neck 
(SCCHN) or esophagus in China (Xia et al. 2004). Combination treatment with 5-fluorouracil 
(5-FU) and cisplatin resulted in a doubling of the response rate compared with chemotherapy 
alone (78.8% versus 39.6%). This is the first randomized demonstration of safety and efficacy 
of oncolytic viruses in humans. The virus dose, chemotherapy regimen, injection procedure, 
and results were very similar to an earlier independent phase II trial performed in USA (Khuri 
et al. 2000). As a result, H101 has been approved by the Chinese government for use in 
combination with chemotherapy for the treatment of head and neck cancers. 
 
  
Table 1. Clinical trials with ONYX-015 and H101. 
Phase Cancer Pts Route Combination Results Ref. 
I SCCHN 22 i.t. - 1x1011 pfu 
3 PR, 2 MR 
 
Ganly et al.  
2000 
I pancreatic 23 i.t. - 1x1011 pfu 
no responses 
 
Mulvihill et al. 
2001 
I metastatic solid 
tumor 
10  i.v. - 2x1013 VP  
no responses 
 
Nemunaitis et al. 
2001a 
I CLM 11 i.ha. 5-FU and 
leukovorin 
2x1012 VP  
1 PR with combination 
 
Reid et al.  
2001 
I ovarian 16 i.p. - 1x1011 pfu for 5d 
no responses 
 
Vasey et al.  
2002 
I colon 5 i.v. 5-FU and CPT-11 2x1012 VP 
no responses 
 
Nemunaitis et al. 
2003 
I metastatic solid 
tumor 
5  i.v. IL-2 2x1011 VP 
no responses  
 
Nemunaitis et al. 
2003 
I malignant 
glioma 
 
24 intra- 
cerebral 
- 1x1010 pfu 
no responses 
Chiocca et al. 
2004 
I metastatic solid 
tumor 
9 i.v. enbrel 1x1012 VP 
weekly for 4w 
no responses 
 
Nemunaitis et al. 
2007 
I-II HCC and CLM 16 i.t 
i.ha. 
i.v. 
 
5-FU in phase II 3x1011 pfu 
no responses 
 
Habib et al.  
2001 
24 
 
 I-II pancreatic 21 i.t. gemcitabine 2x1011 VP  
8 injections over 8w 
2 PR 
 
Hecht et al.  
2003 
I-II premalignant 
oral dysplasia 
22  m.w. - 1x1011 pfu for 5d 
followed by 1 dose/w 
for 5w 
2 CR, 1 PR 
 
Rudin et al.  
2003 
I-II advanced 
sarcoma 
6 i.t. MAP 5x1010 pfu 
1 PR 
 
Galanis et al. 
2005 
I-II metastatic 
colorectal 
24 i.ha 5-FU and 
leukovorin 
2 PR  
 
 
Reid et al.  
2005 
II SCCHN 37  i.t. 5-FU and cisplatin 1x1010 pfu for 5d 
8 CR, 11 PR 
 
Khuri et al.  
2000 
II SCCHN 14 i.t. 5-FU and cisplatin 1x1010 pfu for 5 d 
3 CR, 3 PR 
 
Lamont et al. 
2000 
II SCCHN 37 i.t. - 1x 1010 pfu twice/d for 
10d  
2 CR, 3 PR 
 
Nemunaitis et al. 
2000 
II SCCHN 40 i.t. - 2x1011 VP twice/d for 
10d 
3CR, 2 PR 
 
Nemunaitis et al. 
2001b 
II HCC 10 i.t. 
i.v. 
- 3x1011 pfu 
1 PR 
 
Habib et al.  
2002 
II gastrointestinal 
cancer 
metastatic to 
liver 
27 i.ha. 5-FU and 
leukovorin 
2x1012 VP 
3 PR 
Reid et al.  
2002 
II hepatobiliary 
carcinoma 
20 i.t. 
i.p. 
- 3x1010 pfu 
1 PR 
 
Makower et al. 
2003 
II metastatic 
colorectal 
18 i.v. 
 
- 2x1012 VP every 2w 
no responses 
 
Hamid et al.  
2003 
II SCCHN 15 i.t. - 1x1010 pfu 
virus detected in 10/15 
tumors 
 
Morley et al.  
2004 
II  
(H101) 
late stage cancer 50 i.t.  5-FU and cisplatin 5x1011 VP daily for 5d 
3 CR and 11 PR 
 
Lu et al.  
2004 
III 
(H101) 
SCCHN 123 i.t. 5-FU and cisplatin 
or adriamycin 
1.5x1012 VP daily for 
5d 
79% response in 
combination treatment 
Xia et al.  
2004 
Abbreviations: Pts, patients; SCCHN, squamous cell carcinoma of the head and neck; CLM, colorectal  liver 
metastasis; HCC, hepatocellular carcinoma; i.t., intratumoral; i.p., intraperitoneal; i.v., intravenous; i.ha., 
intrahepatic artery; m.w., mouth wash; 5-FU, 5-fluorouracil; CPT-11, irinotecan; IL-2, interleukin 2;  MAP, 
mitomycin-C-doxorubicin-cisplatin; pfu, plaque forming units; VP, viral particle; CR, complete response; PR, 
partial response; d, days; w, weeks. 
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In general, clinical data with E1B-55 kD-deleted viruses point to the need for more effective 
and selective viruses. Two phase I trials have been completed with a derivative of ONYX-015 
that expresses bacterial cytosine deaminase (CD) and herpes simplex virus thymidine kinase 
(TK) suicide genes (Freytag et al. 2002a, Freytag et al. 2003) (table 2). Intraprostatic Ad5-
CD/TKrep combined with prodrug treatment resulted in a transient drop in PSA levels, but no 
long-term responses were observed. Recently, Freytag et al. (2007b) carried out a phase I trial 
with their second-generation oncolytic adenovirus armed with improved suicide genes and 
adenovirus death protein (ADP) in combination with radiotherapy. No dose-limiting toxicities 
were observed after the treatment. 
 PSA and rat probasin promoters have been utilized for prostate cancer-specific 
replication. CG7060 has a PSA promoter and enhancer controlling E1A expression 
(Rodriguez et al. 1997). In a phase I trial of locally recurrent prostate cancer, CG7060 was 
well tolerated following intraprostatic injection and resulted in dose-dependent reductions in 
PSA in some patients (DeWeese et al. 2001). Similar results were obtained in a phase I/II 
dose escalation trial with intraprostatic CG7870 (DeWeese et al. 2003), which has a rat 
probasin promoter to control E1A and a PSA promoter and enhancer to drive E1B (Yu et al. 
1999). In contrast to CG7060, this virus has an intact E3 region. CG7870 was recently 
delivered i.v. to patients with hormone-refractory metastatic prostate cancer (Small et al. 
2006). Although PSA levels decreased in some patients, neither partial nor complete formal 
PSA responses were observed. 
 
 
Table 2. Clinical trials with other oncolytic adenoviruses. 
Virus Phase Cancer Pts Route Combination Results Ref. 
Ad5- 
CD/TKrep 
I prostate  16 i.t. GCV and 5-FC 1x1012 VP 
≥50% PSA decrease in 
3/16 patients 
Freytag et al. 
2002a, 
Freytag et al. 
2007c 
Ad5-
CD/TKrep 
I prostate 15 i.t. GCV, 5-FC and 
radiation 
1x1012 VP  
significant decline in PSA 
level in all patients 
 
Freytag et al. 
2003 
Ad5-yCD/ 
mutTKSR39 
rep-ADP 
I prostate 9 i.t. GCV, 5-FC and 
radiation 
1x1012 VP x 2 
significant decline in PSA 
level in all patients 
 
Freytag et al. 
2007b 
CG7060 
(CV706) 
I prostate 20 i.t. - 1x1013 VP 
50% PSA decrease in two 
highest dose levels 
 
DeWeese et 
al. 2001 
CG7870 
(CV787) 
I prostate 23 i.v. - 6x1012 VP 
no responses 
Small et al. 
2006 
Abbreviations: Pts, patients; i.t., intratumoral; i.v., intravenous; GCV, ganciclovir; 5-FC, 5-fluorocytosine; PSA, 
prostate specific antigen; VP, viral particle. 
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4. Improving safety and efficacy of oncolytic virotherapy 
 
Oncolytic adenoviruses have demonstrated tremendous efficacy as single agents in preclinical 
model systems featuring human xenograft tumors in immune-deficient mice. Unfortunately, 
while the safety of this approach has been excellent in human clinical trials, complete 
eradication of solid tumors rarely occurs (Liu & Kirn 2008). Therefore, efforts are underway 
to improve the potency of these agents. Several strategies are currently being explored to 
enhance the transduction of target cells and effective penetration of tumor masses. 
Furthermore, maximizing the clinical benefits to patients might require combination therapies 
with conventional approaches. Finally, an important aspect for the future is to improve safety 
of oncolytic agents, as treatment with more potent viruses and combination regimens may 
increase the risk for undesired side-effects.  
 
4.1 Targeting oncolytic adenoviruses to cancer cells 
Various previously described targeting moieties have been introduced into oncolytic 
adenoviruses to increase the transduction of tumor cells. Ad5-Δ24-RGD features a 24-bp 
deletion in E1A and a RGD motif in the fiber (Suzuki et al. 2001). This virus has displayed 
enhanced oncolytic potency in many tumor types, especially against glioma (Lamfers et al. 
2002, Fueyo et al. 2003, Lamfers et al. 2007, Alonso et al. 2008)  and gynecological cancers 
(Bauerschmitz et al. 2002, Lam et al. 2003, Bauerschmitz et al. 2004). Ad5-Δ24-RGD was 
able to replicate efficiently in ovarian cancer primary cell spheroids and resulted in improved 
survival in an orthotopic model of ovarian cancer. Recently, the safety profile of i.p.-delivered 
Ad5-Δ24-RGD was evaluated (Page et al. 2007), and the virus is currently in clinical trials for 
the treatment of recurrent malignant glioma and ovarian cancer 
(www.wiley.co.uk/genmed/clinical).  
 Ad5/3-Δ24 is another pRb-p16 pathway selective adenovirus, whose knob region has 
been pseudotyped from Ad5 to Ad3. This Ad3 receptor-targeted oncolytic agent has 
previously been demonstrated to deliver a powerful antitumor effect to ovarian cancer cells in 
vitro, to clinical ovarian cancer specimens, and in orthotopic models of ovarian cancer 
(Kanerva et al. 2003, Lam et al. 2004). In addition, Ad5/3-Δ24 has shown increased 
therapeutic efficacy in other tumor types as well (Kangasniemi et al. 2006, Guse et al. 2007b). 
Ad5/3 fiber chimeric oncolytic adenoviruses based on SLPI (Rein et al. 2005), CXCR4 
(Rocconi et al. 2007), survivin (Zhu et al. 2008), and mesothelin (Tsuruta et al. 2008) 
promoters have been recently studied as promising candidates for treatment of metastatic 
ovarian cancer. Further, even triple-targeted adenoviruses have been developed in order to 
enhance infectivity and specificity towards cancer cells. Bauerschmitz et al. (2006) 
27 
 
engineered an Ad3 receptor-targeted oncolytic adenovirus featuring cox-2 promoter-driven 
variants of the E1A gene. Ad5/3-cox2LΔ24 demonstrated increased selectivity in ovarian 
cancer cells compared with normal cells and a therapeutic benefit in ovarian cancer xenografts 
(Bauerschmitz et al. 2006, Guse et al. 2007a).    
 
4.2 Combination with conventional therapies 
A powerful approach for increasing the efficacy of virotherapy is utilization of oncolytic 
adenoviruses in combination with traditional anticancer therapies in a multimodal antitumor 
approach (Post et al. 2003). Oncolytic tumor killing differs mechanistically from conventional 
therapies, and therefore, additive or even synergistic effects are possible. The toxicity profiles 
of the treatments may be different and could result in enhanced therapeutic efficacy without 
increased side-effects. Cross-resistance, common for chemotherapeutics, is unlikely since 
agents have different mechanisms of cell killing.  Finally, it may be possible to use lower 
treatment doses and still achieve efficacy.  
 Several preclinical studies with various tumor models have demonstrated improved 
therapeutic efficacy when ONYX-015 has been combined with standard chemotherapeutic 
drugs such as 5-FU, cisplatin, paclitaxel, or doxorubicin (Heise et al. 1997, Heise et al. 2000b, 
You et al. 2000, Portella et al. 2002). Heise et al. (2000b) suggested that the synergistic 
effects were highly dependent on sequencing of the agents. Treatment of SCCHN and ovarian 
cancer xenografts with ONYX-015 prior to or simultaneously with chemotherapy was 
superior to chemotherapy followed by virus treatment. ONYX-015 has also been used in 
conjunction with chemotherapy in several human clinical trials, providing evidence of 
synergistic interactions and safety of the approach (table 1). The most encouraging results 
were seen in a phase II trial of i.t.-delivered ONYX-015 in combination with 5-FU and 
cisplatin against SCCHN (Khuri et al. 2000). The treatment resulted in 27% complete and 
36% partial responses. The combined treatment was well tolerated, with no apparent increase 
in toxicity compared with a single treatment. Similar results were obtained with the related 
virus H101 (Lu et al. 2004, Xia et al. 2004). Ad5-Δ24 has been successfully combined with 
CPT-11 for the treatment of glioma cells in vitro and in vivo (Gomez-Manzano et al. 2006). 
Administration of Ad5-Δ24 potentiated the chemotherapy-mediated antitumor effect without 
modifying the replicative phenotype of the virus. The use of Ad5-Δ24-RGD and everolimus 
has also been evaluated (Alonso et al. 2008). Combination treatment resulted in induction of 
autophagy in vitro and an enhanced antiglioma effect in tumor-bearing animals. Icovir-5 is an 
Ad5-Δ24-RGD-based oncolytic adenovirus containing an insulated form of the E2F-1 
promoter and the Kozak sequence upstream of viral E1A (Alonso et al. 2007a, Cascallo et al. 
2007). Recently, Icovir-5 was given in conjunction with everolimus and temozolomide 
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against glioma, with promising results (Alonso et al. 2007b). Numerous other preclinical 
studies have suggested enhanced cell killing and synergistic activity when oncolytic 
adenoviruses and chemotherapeutic agents are combined (Li et al. 2001, Yu et al. 2001, 
Fujiwara et al. 2006, Hoffmann et al. 2006, Mantwill et al. 2006, Pan et al. 2007a, Pan et al. 
2007b, Ganesh et al. 2008a, Lei et al. 2008).   
 The combination of ONYX-015 and radiotherapy has exhibited an additive antitumor 
effect in colon carcinoma (Rogulski et al. 2000a) and glioma (Geoerger et al. 2002) animal 
models, as well as in thyroid cancer cells in vitro (Portella et al. 2003) Importantly, the level 
of viral replication in vitro after radiation exposure was not significantly reduced even with 20 
Gy. Other oncolytic adenoviruses that have been studied with radiotherapy include Ad5-
CD/TKrep and its second-generation variant (Freytag et al. 1998, Rogulski et al. 2000b, 
Freytag et al. 2002b, Freytag et al. 2003, Freytag et al. 2007a, Freytag et al. 2007b), CG7060 
(Chen et al. 2001), CG787 (Dilley et al. 2005), Ad5-Δ24 (Idema et al. 2007), and Ad5-Δ24-
RGD (Lamfers et al. 2002, Lamfers et al. 2007). 
 
4.3 Armed oncolytic adenoviruses 
A useful approach for further enhancing the oncolytic potency of replicating agents is to arm 
viruses with therapeutic transgenes such as genes encoding prodrug-converting enzymes 
(figure 6), a.k.a. suicide genes (Hermiston & Kuhn 2002). The TK/GCV system is one of the 
most studied prodrug strategies in gene therapy. The approach is based on delivery of a gene 
encoding herpes simplex virus TK, which can convert systemically administered nonharmful 
prodrug ganciclovir (GCV) into a cytotoxic metabolite. TK phosphorylates GCV to its 
corresponding monophosphate, and cellular kinases further phosphorylate it into a toxic 
triphosphate form (Miller & Miller 1980). This can be incorporated into DNA, resulting in 
chain termination, DNA damage, and ultimately cell death (Ilsley et al. 1995, Haynes et al. 
1996, Thust et al. 1996). This system is associated with killing of uninfected neighboring cells 
(bystander effect) (van Dillen et al. 2002). Reports combining the TK/GCV system with 
replicating adenoviruses have been rather controversial. Some studies demonstrate that the 
antitumor efficacy of TK-expressing oncolytic adenoviruses is enhanced by treatment with 
GCV (Wildner et al. 1999a, Wildner et al. 1999b, Nanda et al. 2001). Other reports suggest 
that GCV does not further improve the oncolytic potential of replicating adenoviruses, at least 
not in vivo (Morris & Wildner 2000, Rogulski et al. 2000b, Wildner & Morris 2000, 
Lambright et al. 2001, Hakkarainen et al. 2006). Interestingly, most studies showing enhanced 
efficacy with the TK/GCV system have been performed with viruses with low oncolytic 
potential, but its utility in combination with highly effective infectivity-enhanced viruses is 
unknown.  
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 Other common prodrug-converting enzymes utilized in the context of replicating 
adenoviruses include bacterial or yeast CD (Bernt et al. 2002, Fuerer & Iggo 2004, Conrad et 
al. 2005, Liu & Deisseroth 2006) and rabbit carboxylesterase (CE) (Stubdal et al. 2003, 
Oosterhoff et al. 2005), which are combined with 5-fluorocytosine (5-FC) and irinotecan 
(CPT-11), respectively. Double suicide gene therapy with the TK and CD fusion gene has 
proven useful both preclinically (Freytag et al. 1998, Rogulski et al. 2000b, Freytag et al. 
2002b, Barton et al. 2006, Freytag et al. 2007a), and in clinical trials (Freytag et al. 2002a, 
Freytag et al. 2003, Freytag et al. 2007b). 
 Finally, transgenes encoding tumor suppressor proteins (p53), immunostimulatory factors 
(cytokines), or proteins that target the tumor microenvironment (relaxin, matrix 
metalloproteinases) have been successfully coupled with the lytic capability of the replicating 
adenovirus (Sauthoff et al. 2002, van Beusechem et al. 2002, Geoerger et al. 2004, Kim et al. 
2006, Ramesh et al. 2006, Su et al. 2006, Zhao et al. 2006, Cheng et al. 2007b, Ganesh et al. 
2007, Lei et al. 2008, Luo et al. 2008) . 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Principle of gene-directed enzyme prodrug therapy. Delivery and expression of a suicide gene results 
in conversion of a non-toxic prodrug into a cytotoxic metabolite. This leads to cell death and eradication of 
surrounding cells (bystander effect).    
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4.4 Safety switch strategies 
Improved understanding of adenovirus biology and its interactions with cellular proteins and 
the immune system has allowed creation of more potent viruses for cancer gene therapy. 
However, with more effective therapy regimens, an increase in undesired side-effects may 
occur. The potential for adenovirus-associated toxicity is corroborated by reports of severe 
toxicity in immunocompromised patients (Kojaoghlanian et al. 2003), and a fatality in an 
adenoviral gene therapy trial (Raper et al. 2003). Therefore, termination of viral replication 
when necessary would be useful (safety switch). 
 Adenoviruses do not inherently possess a mechanism for inactivation. Further, no 
formally approved antiviral therapy exists for adenovirus infections, although some promising 
agents have emerged. Most compounds reported to have anti-adenovirus activity, such as 
cidofovir and ribavirin, are nucleoside or nucleotide analogs that target the adenovirus DNA 
polymerase and subsequently inhibit DNA replication (Naesens et al. 2005, Lenaerts & 
Naesens 2006). Cidofovir has been successfully used in clinical studies for adenovirus 
infections (Ljungman et al. 2003), and its antiviral activity against oncolytic adenovirus 
Telomelysin has been evaluated in vitro (Ouchi et al. 2008). Administration of cidofovir 
suppressed the cytopathic effect and decreased the E1A copy number in lung cancer cells. 
Other pharmacological agents with antiviral activities include the antipsychotic agent 
chlorpromazine and the natural bioflavonoid apigenin. Chlorpromazine prevents endosomal 
uptake of viruses by inhibiting the assembly of clathrin adapter protein AP-2 on clathrin 
coated pits, which causes the pits to disappear from the cell surface (Wang et al. 1993). 
Apigenin is a potent cytostatic agent (Patel et al. 2007) that exerts its effects on the cell cycle 
by activating a reversible G2/M and G0/G1 arrest, inhibiting the induction of S phase and 
DNA synthesis (Sato et al. 1994, Lepley & Pelling 1997, Wang et al. 2000, Yin et al. 2001). 
 Another mechanism for increasing safety is to use regulatable gene expression systems 
(Goverdhana et al. 2005). Promoters that are responsive to a variety of environmental or 
physiological changes can be placed to drive expression of a transgene or viral genes. 
Promoters activated by radiation or hypoxia have been commonly used in gene therapy 
(Hallahan et al. 1995, Ido et al. 2001, Binley et al. 2002, Greco et al. 2006, Mezhir et al. 
2006). Regulation can also be achieved by inducing promoters with certain chemical agents 
such as tetracycline (Hillen & Berens 1994, Fechner et al. 2003). Recently, Kanerva et al. 
(2008) evaluated the effect of anti-inflammatory agents on the activity of cox-2 and vascular 
endothelial growth factor (VEGF) promoters.    
 Finally, as many common prodrugs act by inhibiting DNA synthesis, suicide genes may 
also be utilized as a fail-safe mechanism in the case of uncontrolled viral replication (Wildner 
et al. 2003).  
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4.5 Other approaches 
Adenoviruses are highly immunogenic in nature, and immune responses towards the vector 
are a major hurdle for long-term gene expression and oncolytic potency. Successful gene 
transfer applications usually require readministration of virus, the efficacy of which may be 
inhibited by induction of NAbs. A serotype switch is a straightforward strategy for facilitating 
retreatment with adenoviruses. Treatment is based on alternating related viruses with capsids 
from different serotypes or even different species with the rationale that second administration 
would not encounter a neutralizing response (Mastrangeli et al. 1996, Moffatt et al. 2000, 
Sarkioja et al. 2008). Adenoviruses can be masked with synthetic molecules to circumvent 
recognition by the immune system. Vectors coated with polyethylene glycol polymers (PEGs) 
(O'Riordan et al. 1999, Croyle et al. 2001, Fisher et al. 2001) or encapsulated into silica gel 
implants (Kangasniemi et al. 2009) have been utilized to evade the neutralizing effect. An 
intriguing recent approach to improve the bioavailability of vectors while remaining hidden 
from the immune system takes advantage of tumor-homing cells as carriers of oncolytic 
adenoviruses (Komarova et al. 2006, Hakkarainen et al. 2007). Further, pre/co-administration 
of vector with immunosuppressive agents, such as cyclophosphamide, results in transient 
block of NAbs and can increase the duration of transgene expression (Smith et al. 1996, 
Lamfers et al. 2006). Other methods that have been explored to avoid immune attack towards 
adenovirus involve depletion of Kupffer cells (Schiedner et al. 2003, Ranki et al. 2007) and 
physical removal of NAbs by using immunopheresis, or an adenovirus capsid protein column 
(Rahman et al. 2001). 
  An alternative approach to ECM-modifying transgenes is pre/co-treatment with 
proteolytic enzymes or vaso-active compounds that alter the tumor microenvironment 
(Kuriyama et al. 2001, Cairns et al. 2006, Ganesh et al. 2008b). Furthermore, increasing 
oxygenation of tumors to relieve hypoxia and to lower the interstitial pressure has been 
proposed to facilitate drug delivery and dissemination by normalizing the vasculature 
(Minchinton & Tannock 2006).  
  
5. Ovarian cancer 
 
Ovarian cancer is the leading cause of mortality from gynecological malignancies in 
developed countries (Parkin et al. 2005). In Finland, it is the ninth most common cancer 
among women, with 457 new cases in 2006, and the fifth cancer-related cause of death 
(www.cancerregistry.fi). The median age at diagnosis is 62 years, and the risk for disease 
increases with age.  
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 Ovarian carcinomas, tumors originating from the surface epithelium, account for 
approximately 85% of all malignant ovarian tumors and exhibit several histological subtypes 
with different pathogenesis and outcome (Heintz et al. 2001). The most common histological 
types of epithelial ovarian carcinoma are serous, endometroid, and mucinous carcinoma, 
representing 50%, 15%, and 15% of all cases, respectively. Due to mild early symptoms and 
lack of available screening methods, most cases of ovarian cancer are diagnosed at an 
advanced stage resulting in poor prognosis. Approximately 75% of patients are at 
International Federation of Gynecology and Obstetrics (FIGO) stages II-IV at the time of 
diagnosis. Long-term survival of patients with metastatic disease rarely exceeds 15-30%.   
   The most common approach for the treatment of ovarian cancer is cytoreductive surgery, 
followed by systemic chemotherapy (McGuire & Markman 2003). Today, a combination 
therapy with carboplatin and paclitaxel is utilized as a first-line chemotherapy regimen in 
most cases. Although these therapies often provide initial responses, drug resistance 
eventually occurs and disseminated disease cannot be cured. Therefore, the management of 
recurrent ovarian cancer remains difficult, and novel treatment approaches are needed. 
Adenoviral cancer gene therapy is an attractive modality for ovarian cancer, as tumor tissues 
preferentially disseminate throughout the peritoneal cavity, allowing a degree of 
compartmentalization and creating a rationale for direct locoregional delivery. Some of the 
harmful side-effects of systemic treatment may thus be circumvented. Growing evidence 
suggests that patients with microscopic residual disease might benefit from i.p. treatment 
(Armstrong et al. 2006).  
 
5.1 Adenoviral gene therapy trials for ovarian cancer 
Most adenoviral gene therapy trials for ovarian cancer have been carried out with replication-
deficient vectors encoding a therapeutic transgene. Mutation of the p53 tumor suppressor 
gene is one of the most frequent genetic changes in cancer. Alterations of the p53 gene have 
been found in nearly 60% of advanced ovarian cancers (Shahin et al. 2000). Preclinical 
studies have demonstrated that adenovirus-mediated delivery of wild-type p53 inhibits growth 
of ovarian cancer cells both in vitro and in vivo (Santoso et al. 1995, Mujoo et al. 1996). 
Adp53, a recombinant adenovirus encoding human wild-type p53, was evaluated in a phase 
I/II trial, and i.p. virus treatment was well tolerated (Buller et al. 2002a, Buller et al. 2002b). 
In phase I trial, patients received a single injection of the virus, while in phase I/II they were 
treated with multiple doses of up to 7.5 x 1013 viral particles (VP) for five consecutive days. 
Gene transfer and biological acitivity were also demonstrated (Wen et al. 2003). Promising 
data led to a randomized phase II/III trial, where Adp53 was given i.p. in combination with 
chemotherapy (Zeimet & Marth 2003). However, the first interim analysis suggested a lack of 
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therapeutic effect and increased toxicity, and the study was closed. Recently, Wolf et al. 
(2004) completed a phase I trial of multiple-dose Adp53 given i.p. to patients with chemo-
resistant ovarian cancer. Again, the treatment was well tolerated, but no response was 
detected.  
 Growth factor receptors can be utilized as a target for replacement or inactivation. 
Deshane et al. (1994) constructed a gene that encodes an intracellular single-chain antibody 
(intrabody) against the growth factor receptor erbB2 (HER-2/neu). The receptor is highly 
expressed in 10-15% of ovarian cancers and has a correlation with poor prognosis (Slamon et 
al. 1989). Adenovirus (Ad21)-mediated transfer of an anti-erbB2 intrabody to ovarian tumors 
resulted in induction of apoptosis and cytotoxicity in vitro, and enhanced efficacy and 
survival in animal models of ovarian cancer (Deshane et al. 1995a, Deshane et al. 1995b, 
Deshane et al. 1996). The intrabody strategy was also evaluated in a phase I trial (Alvarez et 
al. 2000a). Treatment with Ad21 i.p. up to a dose of 1 x 1011 plaque-forming units (pfu) was 
well tolerated without dose-limiting toxicity. Gene transfer and expression of transgene were 
demonstrated, but no response was detected.  
 Based on promising preclinical results (Rosenfeld et al. 1995, Tong et al. 1996), Alvarez 
et al. (2000b) utilized i.p. delivery of a replication-deficient adenovirus (AdHSV-TK) 
combined with i.v. GCV. A single viral dose from 1 x 109 to 1 x 1011 pfu was followed by 14 
days of GCV. No dose-limiting virus-related side-effects were seen, and 38% of patients had 
stable disease. However, no objective responses were detected. The presence of transgene 
could be detected from ascites samples of patients. Another phase I study combined i.p. 
delivery of AdHSV-TK with i.v. administration of acyclovir and topotecan (Hasenburg et al. 
2000). With doses ranging from 2 x 1010 to 2 x 1013 VP, no dose-limiting adverse effects were 
seen, and the most common side-effect was myelosuppression, with grade 3-4 
thrombocytopenia and neutropenia most likely related to chemotherapy. The median survival 
of these patients was 18.5 months (Hasenburg et al. 2001). 
 The only completed ovarian cancer trial with oncolytic adenovirus was carried out with 
ONYX-015 (Vasey et al. 2002).  In the phase I trial, 16 patients received 1-4 cycles of 
ONYX-015 i.p. on five consecutive days at doses from 1 x 109 to 1 x 1011 pfu. Treatment 
resulted in grade 3 abdominal pain and diarrhea in one patient, but the maximum-tolerated 
dose was not reached. The presence of viral DNA was detected for up to 10 days after the 
final infusion, suggesting viral replication. Disappointingly, no clinical or radiological 
responses were observed in any of the patients.  
 Importantly, none of the above-described trials were randomized. Recent randomized, 
controlled trials with i.t.-delivered AdHSV-TK + GCV (Immonen et al. 2004) and Adp53 + 
radiation (Pan et al. 2008) against glioma and nasopharyngeal carcinoma, respectively, 
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demonstrate that even treatment with replication-deficient first-generation vectors can result 
in enhanced antitumor efficacy and increased survival. 
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AIMS OF THE STUDY 
 
1. To evaluate the antitumor efficacy of Ad5/3-Δ24 in combination with conventional 
chemotherapeutic agents against ovarian cancer in vitro and in vivo (I-II).  
 
2. To analyze the effect of dose and scheduling of i.p.-delivered Ad5/3-Δ24 in vivo. We 
investigated whether multiple i.p. injections are superior to a single dose, and 
determined the lowest effective dose of the virus (II). 
 
3. To construct Ad5/3-Δ24-TK-GFP, a serotype 3 receptor-targeted pRb-p16 pathway-
selective oncolytic adenovirus containing the herpes simplex virus thymidine kinase-
green fluorescent protein (TK-GFP) fusion gene in the partly deleted E3 region. 
Functionality of the virus was examined in vitro as well as in vivo (III). 
 
4. To evaluate the effect of chlorpromazine, an inhibitor of clathrin-dependent 
endocytosis, and apigenin, a cell cycle regulator, on adenovirus replication and 
associated toxicity in vitro and in vivo (IV). 
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MATERIALS AND METHODS 
 
1. Cell lines and fresh human liver tissue 
 
All cell lines (table 3) were cultured in the recommended growth medium supplemented with 
10% FCS, 2 mM L-glutamine, and penicillin-streptomycin solution. Cells were maintained in 
a humified atmosphere at 37°C and 5% CO2. 
  
Table 3. Human cell lines used in this study. 
Cell line Description Source Study 
293 Transformed embryonic 
kidney cells 
ATCC (Manassas, VA, USA) I-IV 
A549 Lung adenocarcinoma cells ATCC (Manassas, VA, USA) I-IV 
MDAH 2774 Ovarian adenocarcinoma cells ATCC (Manassas, VA, USA) III 
SKOV3.ip1 Ovarian adenocarcinoma cells Dr. J Price (M.D. Anderson Cancer Center, 
Houston, TX, USA) 
I-IV 
SKOV3-luc Ovarian adenocarcinoma cells 
expressing firefly luciferase 
Dr. R Negrin (Stanford Medical School, 
Stanford, CA, USA) 
III 
Hey  Ovarian adenocarcinoma Dr. J Wolf (M.D. Anderson Cancer Center, 
Houston, TX, USA)  
I-IV 
OV-4 Ovarian adenocarcinoma Dr. TJ Eberlein (Harvard Medical School, 
Boston, MA, USA) 
III-IV 
 
Permission for studies on human tissue was obtained from the ethics committee prior to 
experiments. Fresh liver samples (IV) were received from healthy donor livers that were to be 
transplanted into recipients (Department of Surgery, Helsinki University Central Hospital). 
Livers were kept on ice with ViaSpan solution (Bristol-Myers Squibb Ab, Bromma, Sweden) 
until slicing. Precision-cut slices (250 μm) were cut with a Vibratome 1000 Plus sectioning 
system (Vibratome, St. Louis, MO, USA) and cultured on a rocker at 37°C and 5% CO2 in 
oxygenated William’s Medium E supplemented with 25 mM D-glucose and 50 μg/ml 
gentamycin. 
 
2. Recombinant adenoviruses 
 
To create oncolytic Ad5/3-∆24-TK-GFP, we utilized a plasmid pTHSN-TGL. Briefly, the 
plasmid was constructed by digesting pTHSN (Kanerva et al. 2005), a plasmid containing the 
E3 region of the adenoviral genome, with SunI/MunI, and inserting TK-GFP (Loimas et al. 
1998) into the resulting 965-bp 6.7K/gp19K deletion of E3A (Hawkins et al. 2001). pAdEasy-
1.5/3-∆24-TGL was generated by homologous recombination in Escherichia coli BJ5183 
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cells (Qbiogene Inc., Irvine, CA, USA) between FspI-linearized pTHSN-TGL and SrfI-
linearized pAdEasy-1.5/3-∆24, a rescue plasmid containing the Ad3 knob and a 24-bp 
deletion in E1A (Kanerva et al. 2005).  The genome of Ad5/3-∆24-TK-GFP was released by 
PacI digestion and subsequent transfection of A549 cells. 
 To construct the E1-deleted control virus Ad5/3-TK-GFP, we used PCR amplification to 
engineer BglII/XhoI restriction sites around the TK-GFP gene: 5’-
ACAGATCTCTAGAGGATCTTGGTGGCGTGAA-3’ and 5’-TACTC 
GAGCTAGAGGATCCCCGGCCG-3’. pShuttle-CMV (He et al. 1998) was digested with 
BglII/XhoI, and the TK-GFP fragment was ligated into the multiple cloning site under the 
control of the CMV immediate early promoter to generate pShuttle-CMV-TGL. Homologous 
recombination was performed between pAdEasy-1.5/3 and PmeI-linearized pShuttle-CMV-
TGL to construct pAdEasy-1.5/3-TGL. The genome of Ad5/3-TK-GFP was released by PacI 
and transfected into 293 cells.  
 Ad5/3-∆24-∆gp19K, an oncolytic virus containing a 965-bp deletion in E3A, was 
constructed as above, but without ligating TK-GFP into pTHSN. Characterization and 
production of Ad5/3luc1 and Ad5/3-∆24 have been previously described (Kanerva et al. 
2002a, Kanerva et al. 2003). 
 All recombinant adenoviruses are listed in table 4. Oncolytic and replication-deficient 
viruses were amplified on A549 and 293 cells, respectively, and purified on double cesium 
chloride gradients. The VP concentration was measured at 260 nm, and infectious particles 
were determined by standard plaque assay or TCID50 on 293 cells. Modified viral regions 
were confirmed by polymerase chain reaction (PCR) and sequencing. 
 
Table 4. Recombinant adenoviruses used in this study.  
Virus Description Source Study 
Ad5/3luc1 Ad5 virus with deleted E1/E3 
luciferase gene under CMV promoter replacing E1 
chimeric fiber with receptor-binding knob domain of Ad3 
   
(Kanerva et 
al. 2002a) 
I-II 
Ad5/3-TK-GFP Ad5 virus with deleted E1/E3 
TK-GFP gene under CMV promoter replacing E1 
chimeric fiber with receptor-binding knob domain of Ad3 
   
This study III 
Ad5/3-∆24 Ad5 virus with 24-bp deletion in CR2 of E1A 
chimeric fiber with receptor-binding knob domain of Ad3 
   
(Kanerva et 
al. 2003) 
I-IV 
Ad5/3-∆24-TK-
GFP 
Ad5 virus with 24-bp deletion in CR2 of E1A 
TK-GFP gene under E3 promoter in partly deleted E3  
chimeric fiber with receptor-binding knob domain of Ad3  
This study III 
Ad5/3-∆24-
∆gp19K 
Ad5 virus with 24-bp deletion in CR2 of E1A 
partly deleted E3 
chimeric fiber with receptor-binding knob domain of Ad3  
This study III 
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3. Agents 
 
Gemcitabine (Gemzar®) was purchased from Eli Lilly and Company (Indianapolis, IN, USA) 
(I-II). The stock solution was prepared in 0.9% NaCl. Epirubicin (Farmorubicin®) 2 mg/ml 
solution was obtained from Pharmacia (Vantaa, Finland) (II). GCV was purchased from 
Roche (Espoo, Finland) (III). Stock solution 50 mg/ml was prepared in sterilized water. 
Apigenin and chlorpromazine were purchased from Sigma-Aldrich Finland (Helsinki, 
Finland) (IV). Apigenin stock solution 50 mg/ml was prepared in 1M KOH for in vitro 
studies. For in vivo experiments, 25 mg/ml stocks of chlorpromazine and apigenin were 
prepared in 1% Tween 80 and 0% growth medium, respectively. All agents were further 
diluted in growth medium immediately before use. 
 
4. In vitro experiments 
 
4.1 Cytotoxicity assay (I-IV) 
Cells were seeded at a density of 1 x 104 cells/well on 96-well plates and cultured overnight. 
Briefly, cells were either infected with variable concentrations of viruses or treated with 
agents, or treated with a combination of both. Detailed description of doses and schedules 
utilized in different studies can be found in the original publications. Cells were incubated at 
37°C until almost complete cell killing was visually evident. Thereafter, cell viability was 
measured with the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS assay) 
(Promega, Madison, WI, USA).  
 
4.2 Quantitation of viral replication (I, III-IV) 
Ovarian adenocarcinoma cells were seeded on 6-well plates. The next day, cell monolayers 
were infected with viruses at 10 VP/cell in 1 ml of growth medium with 2% FCS. Detailed 
descriptions of administration of gemcitabine (I), GCV (III), chlorpromazine or apigenin (IV) 
can be found in the original publications. Cells and medium were harvested 24-96 h post-
infection, lysed by three freeze-thaw cycles, and centrifuged at 4000 rpm for 10 min. The 
amount of infectious particles present in the resulting supernatants was determined by plaque 
assay or TCID50 on 293 cells.    
 Liver slices were preincubated with chlorpromazine or apigenin for 1h before 
administration of 107 VP of viruses (IV). Slices and supernatant were frozen separately at the 
indicated time-points. After gradual thaw on ice, slices were minced, combined with 
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supernatant, and freeze-thawed three times. After centrifugation, supernatant was titered on 
293 cells.   
 
4.3 Correlation of viral replication and GFP expression (III) 
Ovarian adenocarcinoma cells were plated at 1 x 104 cells/well on 96-well plates and cultured 
overnight. Cells in 10 replicates were infected with viruses at 0.0001-1000 VP/cell in 100 μl 
of growth medium with 2% FCS. Cells were followed daily for 10 days for CPE, and the 
amount of infectious particles was calculated based on CPE data by the modified TCID50 
method. Cells were imaged daily with a Typhoon 9400 variable mode imager (GE Healthcare 
Life Sciences, Helsinki, Finland) for expression of GFP and images were analyzed with 
ImageQuant 5.20 software (GE Healthcare Life Sciences, Helsinki, Finland). 
 
5. Murine models of ovarian cancer 
 
5.1 Mice (I-IV) 
Three to four-week-old female mice were obtained from Taconic (Ejby, Denmark) and 
quarantined for 2 weeks. All animal experiments were approved by the Experimental Animal 
Committee of the University of Helsinki and the Provincial Government of Southern Finland.  
 Tumors were inoculated i.p. in C.B-17 SCID (severe combined immunodeficiency) mice 
and followed for survival. The health of the mice was monitored daily, and mice were killed 
when there was evidence of pain or distress. Subcutaneous (s.c.) tumors were established in 
flanks of NMRI (Naval Medical Research Institute) nude mice and followed for tumor 
growth. Tumors were measured with a caliper, and mice were killed when tumors reached a 
diameter of 10 mm. Tumor size was calculated by using the formula 0.5 x length x width2. All 
agents were diluted in 500 μl of growth medium for i.p. and 50 μl for i.t. injections. Untreated 
control mice received only growth medium. 
 
5.2 Comparison of single and weekly delivery (II) 
An orthotopic model of ovarian cancer was developed by injecting 3 x 106 Hey cells i.p. On 
day 3 after cell injection, mice were treated i.p. with 1 x 108 VP, or the same dose was given 
weekly on days 3, 10, 17, and 24. In another experiment, the tumors were established by 
injecting 1 x 107 SKOV3.ip1 cells i.p. and treated with a single i.p. injection of 1 x 108 VP on 
day 10, or the same dose was administered weekly on days 10, 17, 24, and 31. 
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5.3 Determination of lowest effective dose (II) 
Mice were injected i.p. with 1 x 107 SKOV3.ip1 cells, and carcinomatosis was allowed to 
develop. On day 10, the control group received growth medium i.p., and treatment groups 
were injected i.p. with 102-106 VP. 
 
5.4 Combination with chemotherapy (I-II) 
Mice were injected i.p. with 1 x 107 SKOV3.ip1 cells and randomized into six treatment 
groups: 1) growth medium i.p. on day 10, 2) 3 x 107 VP of virus i.p. on day 10, 3) 80 mg/kg 
gemcitabine i.p. on days 10, 13 and 16. 4) virus and gemcitabine simultaneously at the same 
doses and schedules as above, 5) virus on day 10 and gemcitabine on days 11, 14, and 17, and 
6) gemcitabine on days 10, 13, and 16 and virus on day 11 (I).  
 In another study, mice received 3 x 106 Hey cells i.p. On days 3, 10, 17, and 24, 40 mg/kg 
gemcitabine and 1 x 108 VP were administered i.p. either alone or together. Alternatively, 1 
mg/kg epirubicin and 1 x 108 VP were given i.p. alone or in combination on days 3, 10, and 
17 (II). 
   
5.5 Combination with ganciclovir (III) 
S.c. xenografts were established by inoculating 5 x 106 SKOV3-luc cells in both flanks of 
nude mice. When tumors reached a diameter of approximately 4-5 mm, mice were 
randomized into six treatment groups.  1 x 108 VP were delivered i.t. on days 7, 8, and 9. A 
second round of viruses was given on days 19, 20, and 21. 50 mg/kg GCV was administered 
i.p. daily, starting 48h after the last virus injection, over one-week periods on days 11-17 and 
23-29.  
 An i.p. model was developed by injecting 5 x 106 SKOV3-luc cells i.p. into SCID mice. 
On day 5, mice were treated i.p. with 1 x 108 VP. 50 mg/kg GCV was given daily for 14 days, 
starting 48h after virus delivery.  
 
5.6 Noninvasive imaging (III)  
Mice were imaged using an IVIS 100 imaging system (Xenogen, Alameda, CA, USA) to 
detect expression of luciferase or GFP. For bioluminescence imaging, 150 mg/kg D-luciferin 
(Promega, Madison, WI, USA) was injected i.p., and images were captured 10 min after 
injection. Photographic and bioluminescence/fluorescence images were overlaid by using 
Living Image software 2.50 (Xenogen, Alameda, CA, USA). Total flux (photons/s) was 
measured by drawing regions of interest (ROIs) around tumor areas, enclosing all emitted 
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signals. Background was subtracted by measuring same-sized ROIs in areas without light 
emission. 
 
5.7 Inhibition of viral replication (IV) 
5 x 106 Hey cells were injected in both flanks of nude mice. Mice were treated i.t. with 3 x 
108 VP on days 0, 2, and 4. Mice received 200 μg chlorpromazine or 250 μg apigenin i.p. 
daily.  
 In replication assay, Hey tumors were established as above. Mice were treated i.t. with 3 
x 108 VP on day 0. Chlorpromazine or apigenin was given as above. Tumors were harvested 
and homogenized, and virions were released by three freeze-thaw cycles. Infectious particles 
were determined by TCID50. 
 For development of a toxicity model, 1 x 107 SKOV3.ip1 cells were injected i.p., after 
which mice received 3 x 107 VP i.p. on day 10. Chlorpromazine or apigenin was thereafter 
administered daily. Further, all mice received 80 mg/kg gemcitabine i.p. on days 11, 14, 21, 
and 24.   
 
5.8 Histopathology (I-II, IV) 
Livers and residual tumors were collected and fixed in buffered formalin (10%), embedded in 
paraffin, and cut into 5 μm sections. Deparaffinized specimens were stained with hematoxylin 
and eosin. Histopathology was scored blinded by an independent pathologist. 
 
6. Statistical analysis (I-IV) 
 
In combination studies in vitro (I-II), Chou and Talalay’s (1983) median-effect method was 
used to calculate combination index (CI) values under the assumption of mutually 
nonexclusive drug interactions using S-PLUS 6.0 (Insightful Corporation, Seattle, WA, 
USA). CI <1 indicates synergism, CI=1 additivity, and CI>1 antagonism. One sample t-test 
was performed to determine whether the mean CI values from separate experiments at 
multiple-effects levels were significantly different from a value of 1.0.  
 One-way analysis of variance with Bonferroni’s post-hoc test for multiple comparisons 
was used for statistical analysis of the effect of GCV on cell viability and tumor GFP 
expression data (III) with SPSS 14.0 (SPSS Inc., Chicago, IL, USA).  
 The effects of chlorpromazine or apigenin on replication and cell viability (IV) were 
analyzed by using bootstrap multiple comparisons of means in analysis of variance (PROC 
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MULTITEST SAS 9.1 (SAS Institute Inc., Cary, NC, USA). The levels of viral replication 
were log-transformed for normality.  
 Survival data (I-IV) were plotted in a Kaplan-Meier curve, and groups were compared 
pair-wise with log-rank test using SPSS 14.0. A analyse of tumor volume (III-IV) and photon 
emission (III) were performed using a repeated measures model with PROC MIXED using 
SAS 9.1. Measurements were log-transformed for normality. The effects of treatment group, 
time in days, and the interaction of treatment group and time were evaluated by F-tests.  
Curvature in the models was tested by a quadratic term for time.  The a priori planned 
comparisons of specific differences in predicted treatment means averaged over time and at 
the last time-point were computed by t-statistics. For all analyses, P<0.05 was deemed 
statistically significant.  
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RESULTS AND DISCUSSION 
 
1. Tropism modified oncolytic adenovirus Ad5/3-∆24 in combination 
with chemotherapy (I-II) 
 
Ad5/3-Δ24 is a serotype 3 receptor-targeted pRb-p16 pathway-selective oncolytic adenovirus, 
which has previously been shown to have enhanced antitumor effect in the context of ovarian 
cancer (Kanerva et al. 2003, Lam et al. 2004). Nevertheless, when tested in a highly sensitive 
in vivo imaging assay, evidence emerged that tumors may be able to gain resistance even to 
this highly potent treatment (Kanerva et al. 2005). Therefore, we hypothesized that the 
therapeutic efficacy of Ad5/3-Δ24 might be improved when used in combination with 
chemotherapeutic agents.  
 Most patients with advanced epithelial ovarian cancer will relapse after first-line 
chemotherapy with platinum and taxane compounds. Thus, we chose gemcitabine and 
epirubicin in our experiments as examples of commonly used second-line treatment options 
for platinum/taxane-resistant ovarian cancer (Harries & Gore 2002).   
 
1.1 Combination of Ad5/3-∆24 and gemcitabine in vitro and in vivo (I-II) 
The deoxycytidine analog gemcitabine has been used to treat solid tumors, and the drug has 
demonstrated a therapeutic response in a variety of malignancies, including ovarian cancer 
(Lund et al. 1995, Shapiro et al. 1996, Fowler & Van Le 2003, Markman et al. 2003). The 
drug acts through several different mechanisms that result in self-potentiation of its activity 
(Plunkett et al. 1995). Specifically, gemcitabine is phosphorylated by cellular deoxycytidine 
kinase to mono-, di- and triphosphate forms, of which the latter is the major cellular 
metabolite. It competes with endogenous deoxycytidine triphosphate (dCTP) for 
incorporation into DNA, resulting in chain termination and subsequent inhibition of DNA 
replication and repair mechanisms (Huang et al. 1991). In addition, the diphosphate form of 
the drug decreases the pool of cellular DNA precursors, including dCTP, available for DNA 
synthesis. Reduction in dCTP increases incorporation of the drug into DNA and potentiates its 
cytotoxicity. Reduction of dCTP may also release more deoxycytidine kinase from feedback 
inhibition and increase phosphorylation of gemcitabine (Heinemann et al. 1992). 
 To determine the potential interaction between Ad5/3-Δ24 and gemcitabine in vitro, the 
cell killing effect of the combination treatment was compared with single treatments on 
established ovarian adenocarcinoma cell lines, and synergism was quantitated with Chou and 
Talalay’s (1983) median-effect method. On SKOV3.ip1 cells, analysis revealed significant 
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synergy (P=0.003) when gemcitabine was given concomitantly with Ad5/3-Δ24 (figure 1c in 
I). Infection of cells at 10 VP/cell resulted in 95% survival, whereas 0.2 μg/ml gemcitabine 
showed 62% survival. However, when Ad5/3-Δ24 and gemcitabine were administered 
simultaneously at these concentrations, cell survival decreased to 32%. We also evaluated 
whether sequencing of the agents would have an effect on cytotoxicity. Synergistic activity 
was not seen when the virus was given 24h before or after gemcitabine (P>0.2) (figure 1d and 
1e in I). With regard to Hey cells, viral infection 24h after gemcitabine yielded synergy at a 
dose of 0.2 μg/ml (Figure 2e in I), but when other doses were taken into the analysis, 
significant overall synergy was not evident (P>0.1). This was also the case when cells were 
infected simultaneously or before gemcitabine treatment (P>0.2). Ad5/3luc1 was used as a 
replication-deficient control, and it did not cause oncolysis or potentiation of gemcitabine. 
  As human adenoviruses do not replicate productively in murine tissues (Blair et al. 1989), 
human xenografts in mice were utilized for in vivo studies. The antitumor efficacy of 
combination treatment was evaluated in orthotopic murine models of ovarian cancer. Mice 
were followed for survival and livers were collected and processed for histopathological 
analysis. In the SKOV3.ip1 model (figure 4 in I), the median survival of untreated mice was 
30 days, and gemcitabine increased the median survival to 39 days (P<0.0001). Mice in these 
groups died due to disease progression. In groups receiving the combination regimen, a 
number of early deaths were seen. These were probably due to liver toxicity, manifested as 
either centrilobular or total necrosis of the liver (figure 5 in I). In one mouse treated with 
Ad5/3-Δ24 24h prior to gemcitabine administration, we also saw evidence of hepatic 
extramedullary hematopoiesis. One possible reason for this finding is bone marrow damage 
(Harada et al. 1999). Nevertheless, simultaneous administration of Ad5/3-Δ24 with 
gemcitabine improved the survival of mice in comparison with no treatment (P<0.0001) or 
gemcitabine alone (P=0.0084). While the median survival of mice treated with Ad5/3-Δ24 
was 89 days (P<0.0001 for both mock and gemcitabine), the median survival was not reached 
for Ad5/3-Δ24 given 24h after gemcitabine, as 60% of the mice were alive at the end of the 
experiment on day 130 (P=0.0003 and P=0.0002 for mock and gemcitabine, respectively). 
None of the mice treated with virus alone or in combination with gemcitabine died due to i.p. 
relapse. Instead, mice died due to toxicity of the treatment or were killed because of s.c. 
tumors at the injection site.  
 Combination treatment was also tested in a more aggressive Hey ovarian carcinoma 
model (figure 5a in II). All treatment schedules resulted in significantly enhanced survival 
(P<0.001) compared with untreated mice, whose median survival was 23 days. Animals 
receiving Ad5/3-Δ24 and gemcitabine as a single treatment had an improved median survival 
of 31 and 38 days, respectively, and these treatments did not differ significantly (P=0.096). 
The combination resulted in superior antitumor efficacy compared with Ad5/3-Δ24 (P<0.001) 
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or gemcitabine (P=0.012) alone, and median survival increased to 54 days. In 
histopathological studies (figure 5b and 5c in II), such changes as apoptosis, diffuse necrosis, 
and fibrotic strias were more prominent in the treated tumors, while the group injected with 
growth medium only showed reticular necrosis and necrotic foci (tumor necrosis). However, 
treatment-related deaths were circumvented by utilizing lower doses of gemcitabine. In the 
immune-deficient mice used here, antiviral antibodies are not formed, and liver damage is 
possible. Virus replication might be more abrogated in immunocompetent systems, resulting 
in less hepatic toxicity, while antitumor efficacy might remain due to relative protection from 
the immune system provided by the tumor environment. 
 
1.2 Effect of gemcitabine on Ad5/3-∆24 replication (I) 
One possible mechanism for synergy between Ad5/3-Δ24 and gemcitabine might be that 
chemotherapeutic agents increase the level of viral replication (Yu et al. 2001). Therefore, we 
evaluated the effect of gemcitabine on Ad5/3-Δ24 replication on ovarian cancer cells. Cells 
were infected with the virus alone or in combination with gemcitabine, and the amount of the 
virus at different time-points was determined. The number of infectious particles increased 
more rapidly after infection with Ad5/3-Δ24 alone than with combination treatment (figure 3 
in I). The difference was more than 1000-fold 24h after infection and approximately 100-fold 
after 48h and 72h. However, a plateau was reached for Ad5/3-Δ24 already after 48h, whereas 
viral replication continued to increase in cells treated with the combination regimen. The total 
amount of virus production was similar in both cases approximately 96 h post-infection. Viral 
infection 24h after administration of gemcitabine was also performed, and the number of 
infectious particles measured as above. Again, Ad5/3-Δ24 alone resulted in more than 1000-
fold and 100-fold virus production at 24h and 48h after infection, respectively. Instead of 
increasing the level of viral replication, our results suggest that gemcitabine reduces the rate 
of Ad5/3-Δ24 replication early after infection.  
 
1.3 Combination of Ad5/3-∆24 and epirubicin in vitro and in vivo (II) 
Epirubicin is a derivative of a commonly used anthracycline, doxorubicin, but causes less 
cardiotoxicity (Minotti et al. 2004). The drug has been utilized to treat various cancer types, 
including platinum-resistant ovarian cancer (Pelaez et al. 1996, Vermorken et al. 1999, 
Vermorken et al. 2000). The precise mechanism of action of epirubicin, like other 
anthracyclines, is a matter of controversy. Briefly, the drug intercalates into DNA strands, 
resulting in a complex formation that prevents DNA synthesis (Minotti et al. 2004). It also 
inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex (Tewey et 
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al. 1984). Prevention of religation of cleaved DNA leads to double-strand breaks and cell 
death.  
 The cytotoxicity of Ad5/3-Δ24 and epirubicin in vitro was analyzed on established 
ovarian adenocarcinoma cells. Ad5/3-Δ24 infection of cells with 0.1 VP/cell resulted in 88% 
cell survival, whereas 0.25 μg/ml epirubicin resulted in 63% viability (figure 3b in II). 
However, when both agents were administered together at these doses, the amount of living 
cells decreased to 37%. Thus, the combination resulted in significantly improved cancer cell 
killing compared with single treatments (P=0.002). Again, Ad5/3luc1 was used as a 
replication-deficient control and it did not cause oncolysis (figure 3a in II). 
 To examine whether the combination works synergistically also in vivo, mice with 
advanced ovarian cancer were treated either with single agents or the combination regimen 
(figure 4 in II). All treatment schedules resulted in significantly improved survival (P<0.001) 
compared with untreated mice, which had a median survival of 25 days. Treatment with 
Ad5/3-Δ24 or epirubicin alone enhanced the survival to 32 or 37 days, respectively. No 
significant difference existed between single therapies (P=0.565). However, the combination 
resulted in greater efficacy than the virus (P=0.030) or epirubicin (P=0.022) alone. Median 
survival increased to 42 days and two mice were alive at the end of the experiment on day 50. 
 
1.4 Possible mechanisms for synergistic interactions (I-II) 
The mechanism for synergistic activity between oncolytic adenoviruses and chemotherapeutic 
agents is currently unknown, but several hypotheses can be put forth. First, chemotherapeutic 
agents may affect the level of viral replication. Increased viral production was reported when 
oncolytic adenovirus CV787 was combined with taxane compounds (Yu et al. 2001). Low 
concentration of paclitaxel has also been shown to improve transduction of recombinant 
adenovirus in a dose-dependent manner, resulting in more efficient viral replication (Nielsen 
et al. 1998).  On the other hand, several other studies have demonstrated that cytotoxic drugs, 
such as cisplatin or CPT-11, have no effect on the replication kinetics of oncolytic viruses 
(Heise et al. 2000b, Khuri et al. 2000, Gomez-Manzano et al. 2006, Ganesh et al. 2008a). 
These results are logical since different agents work by different mechanisms of action. Our 
findings suggest that gemcitabine reduces the rate of Ad5/3-Δ24 replication early after 
infection, but does not affect the total virus yield. It is not clear how slower replication 
increases antitumor efficacy, but perhaps enhanced tumor penetration and dissemination 
before oncolysis, and formation of subsequent necrotic areas that are unpenetrable to the virus 
are involved. Further, slower replication could be advantageous with regard to toxicity, 
resulting in less liver damage. However, slow replication could be disadvantageous when 
faced with a mounting immune response.  
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 Second, oncolytic virus may augment the antitumor activity of chemotherapeutics. 
Adenoviral E1A protein expression has been shown to increase cellular sensitivity to 
chemotherapeutic agents in both a p53-dependent and a p53-independent manner (Lowe & 
Ruley 1993, Sanchez-Prieto et al. 1996). The initial molecular mechanism of E1A-mediated 
tumor suppression was downregulation of HER-2/neu proto-oncogene (Yu et al. 1991). Ueno 
et al. (2000) demonstrated that taxane-resistant HER-2/neu-overexpressing SKOV3.ip1 cells 
became sensitive to paclitaxel treatment after downregulation of HER-2/neu by E1A. 
Suppression of NF-κB activation is another mechanism by which E1A promotes apoptosis in 
cells exposed to apoptotic stimuli (Shao et al. 1997). NF-κB is inactive in association with 
unphosphorylated IκB. In response to harmful stimuli, such as chemotherapy, IκB is 
phosphorylated and degraded, leading to activation of NF-κB, which functions as a 
transcriptional factor for the expression of survival genes. E1A inhibits NF-κB activation by 
stabilizing the unphosphorylated form of IκB (Shao et al. 1999). E1A also suppresses the 
expression of poly(ADP-ribose) polymerase (PARP), which plays an important role in DNA 
repair. Recently, E1A was shown to sensitize hepatocellular carcinoma cells to gemcitabine 
(Lee et al. 2003). Interestingly, as a mechanism for gaining resistance, NF-κB and PARP are 
induced in cancer cells treated with gemcitabine, while E1A inhibits NF-κB and PARP, 
consecutively resulting in sensitization of cells to gemcitabine (Lee et al. 2003). These aspects 
may also partially account for the hepatic toxicity seen here. Although human adenoviruses 
do not productively replicate in murine cells, E1A expression and protein production do ensue 
(Hallden et al. 2003). Theoretically, this could sensitize normal cells to gemcitabine-mediated 
damage.  
 Expression of CAR has been reported to be induced with certain chemotherapeutic agents 
such as gemcitabine and etoposide (Hemminki et al. 2003). Although increased receptor 
expression has not been shown for the Ad3 receptor, it could potentially play a role. CD46 has 
been suggested as a possible Ad3 receptor (Sirena et al. 2004, Fleischli et al. 2007), but other 
reports disagree (Gaggar et al. 2003, Short et al. 2004, Marttila et al. 2005). Once the Ad3 
receptor is identified, possible upregulation mediated by chemotherapeutic agents can be 
investigated.  
 Finally, and more unlikely, each agent could work independently on different cell 
populations. Chemotherapeutics may also be able to kill tumor-surrounding stromal cells of 
murine origin, particularly when sensitized with E1A.  
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2. Evaluation of dose and scheduling of intraperitoneally delivered 
Ad5/3-∆24 in ovarian cancer xenografts (II) 
 
Ad5/3-Δ24 is currently under development for human clinical testing. To optimize protocols 
for upcoming clinical trials, determination of wheter multiple rounds of treatment are superior 
to a single dose is warranted. Each ovarian cancer cell infected in vitro rapidly produces 
thousands of new virions. Therefore, we performed in vivo dose de-escalation to test whether 
virus amplification would translate into efficacy at very small doses, which would be 
promising with regard to clinical trials for patients suffering from advanced ovarian cancer. 
To mimic the clinical situation, we utilized orthotopic murine models of peritoneally 
disseminated ovarian cancer to compare survival of mice treated i.p. with either a single viral 
dose or weekly delivery. Further, the lowest effective dose of i.p.-delivered Ad5/3-Δ24 was 
determined. 
 
2.1 Comparison of single and weekly delivery of Ad5/3-∆24 (II) 
Adenoviruses are common pathogens and pre-existing immunity is thought to rapidly clear 
the viruses, and thus, multiple dosing is probably required for successful virotherapy (Bessis 
et al. 2004). Gene therapy trials for ovarian cancer have usually relied on i.p. delivery of the 
agents to patients with peritoneally disseminated disease. The peritoneal cavity of most 
ovarian cancer patients contains malignant ascites fluid with NAbs against adenovirus 
(Hemminki et al. 2002a). These antibodies might inhibit the initial viral infection and further 
spreading of virions. However, previous studies have suggested partial escape of Ad5/3 
pseudotyped viruses from pre-existing Nabs, perhaps due to the chimeric nature of the fiber 
(Kanerva et al. 2002b). Further, repeated delivery of highly potent, infectivity-enhanced viral 
agents might lead to toxicity. Therefore, we evaluated in vivo whether the therapeutic efficacy 
of a single Ad5/3-Δ24 injection differs from that of the weekly delivery schedule.  
 Treatment with a single Ad5/3-Δ24 injection was compared with multiple injections in 
orthotopic murine models of ovarian cancer. Peritoneally disseminated carcinomatosis was 
allowed to develop, and Ad5/3-Δ24 was given i.p. either as a single or a weekly dose of 1 x 
108 VP (figure 1 in II). Both treatment schedules resulted in significantly improved survival 
compared with untreated mice (P<0.001) in both Hey and SKOV3.ip1 in vivo models. 
However, administration of a single viral dose did not differ significantly from several doses 
in either model (P=0.900 and P=0.654, respectively), suggesting effective in vivo replication. 
In aggressively growing Hey xenografts, the median survival of untreated mice was 23 days, 
while single and weekly virus treatments increased the median survival to 35 and 31 days, 
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respectively. All mice died due to tumor progression in the peritoneal cavity. In the 
SKOV3.ip1 model, untreated mice achieved a median survival of 37 days, while single and 
weekly injection schedules enhanced the median survival to 58 and 75 days, respectively. 
Most of the treated mice died due to disease progression, but in a few cases there was 
evidence of hepatic toxicity in both treated groups, a known side-effect of persistent virus 
replication. Our results are consistent with a previous report where single treatment with 
Ad5/3-Δ24 was suggested to be as effective as delivery on three consecutive days (Kanerva et 
al. 2003). However, these survival studies were not carried out in the same experiment, which 
makes direct comparison difficult.   
 
2.2 Determination of lowest effective dose of Ad5/3-∆24 (II) 
The lytic life cycle of adenoviruses results in oncolysis of infected cells and spreading of 
virus progeny to surrounding cells and, at least in theory, this process would be expected to 
continue as long as target cells persist. Further, the intensity of immune responses induced by 
adenoviruses is highly dependent on the vector dose (Bessis et al. 2004). Therefore, we 
examined whether Ad5/3-Δ24 infection with very small doses could lead to therapeutic 
efficacy.   
 The lowest effective i.p. dose of Ad5/3-Δ24 was evaluated in mice with orthotopic 
SKOV3.ip1 tumors. Because 108 VP had previously been found to be effective, dose de-
escalation started from 106 and was continued to 102 VP. Although not significant, there 
seemed to be a trend towards dose-dependency since treatment with the highest dose of 106 
VP resulted in the highest survival rates and a median survival of 83 days (figure 2 in II). 
However, even the lowest viral dose of 102 VP with a median survival of 54 days was 
sufficient to increase the survival of mice significantly compared with untreated animals 
(P=0.001). Slight variations in median survival did not result in different long-term survival, 
as treatment with all doses enhanced the survival significantly compared with untreated 
animals.  
 These findings are consistent with potent amplification of the agent. However, the 
survival curves appear to somewhat favor the higher dose. Although not demonstrated before 
in vivo, even a small amount of virus can amplify exponentially and kill large numbers of 
tumor cells. Nevertheless, given the different tumor characteristics, these findings might have 
been different for other cancer cell lines. Further, results obtained from immune-deficient 
mice do not correlate with the actual situation in clinics, where low doses might be rapidly 
cleared by the immune system. 
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3. Tropism modified oncolytic adenovirus Ad5/3-∆24-TK-GFP and 
utility of TK/GCV suicide gene system (III)   
 
Arming oncolytic adenoviruses with therapeutic transgenes and enhancing transduction of 
tumor cells are useful strategies for eradication of advanced tumor masses (Hermiston & 
Kuhn 2002, Kanerva & Hemminki 2005). The TK/GCV prodrug system is a classic strategy 
based on conversion of systemically administered prodrug GCV to cytotoxic metabolite by 
cellular TK. This approach has been promising when coupled with viruses featuring 
considerably low oncolytic potential (Wildner et al. 1999a, Wildner et al. 1999b), but its 
utility in the context of highly effective infectivity-enhanced viruses is unknown. Therefore, 
we constructed a serotype 3 receptor-targeted, pRb-p16 pathway-selective oncolytic 
adenovirus containing a fusion gene encoding TK and GFP in the partly deleted E3 region 
under the control of endogenous adenoviral gene expression machinery. The aim was to 
examine whether the TK/GCV system increases the oncolytic potency of our newly generated 
virus. Further, we hypothesized that we can follow tumor progression and virus spreading by 
noninvasive imaging technology. 
  
3.1 Verification of virus replication and transgene production (III) 
An approximately 2-kb TK-GFP fusion gene (Loimas et al. 1998) was inserted into the 
6.7K/gp19K-deleted E3A region of a serotype 5-based oncolytic adenovirus featuring the 
serotype 3 fiber knob, resulting in a novel virus Ad5/3-Δ24-TK-GFP (figure 1a in III). This 
insertion site has previously been demonstrated to be ideal for expression of transgenes 
because of tight linkage to virus replication (Hawkins et al. 2001, Kanerva et al. 2005). 
Transgene production begins approximately 8h post-infection, and a heterologous promoter or 
poly-A is not required. Both of these features are useful for retaining the highest possible 
virus replication, and space is saved for maximal transgene size. Ad5/3-TK-GFP, a virus with 
a CMV promoter-driven transgene in the deleted E1 region, was constructed as a replication-
deficient control.  
 To determine whether insertion of the fusion gene had an effect on virus replication, 
Ad5/3-Δ24-TK-GFP was compared with Ad5/3-Δ24-Δgp19K and Ad5/3-Δ24 (figure 1b in 
III). The former is an isogenic virus featuring the corresponding deletion without a transgene, 
and the latter contains an intact E3 region. Ad5/3-Δ24-TK-GFP replicated efficiently and 
resulted in complete killing of all analyzed ovarian cancer lines. However, the replication rate 
was slightly slower, and total production of functional virions remained 1-2 log lower levels 
when compared with the other oncolytic viruses. This may have been due to transgene 
production competing for the cellular resources needed for amplification of the viral genome. 
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Alternatively, because our transgene is 1 kb longer than the deleted E3 fragment, the larger 
genome size may have slowed replication to some extent. Slower replication was not caused 
by deletion of the 6.7K/gp19K gene. In contrast, infection with the isogenic Ad5/3-Δ24-
Δgp19K harboring the same deletion but lacking a transgene resulted in higher replication 
levels and more efficient oncolysis than Ad5/3-Δ24, whose genome is closer to a wild-type 
adenovirus. These results highlight the impact of genome size on speed of adenovirus 
replication.   
 To confirm expression of the TK-GFP fusion product, Ad5/3-Δ24-TK-GFP- and Ad5/3-
TK-GFP-infected ovarian cancer cells were imaged daily for GFP expression (supplementary 
figure 1 in III). Ad5/3-Δ24-TK-GFP-infected cells expressed more GFP than cells infected 
with the replication-deficient virus, and the proportion of GFP-positive cells increased over 
time. By day 10, expression of GFP was seen in cells infected with only 0.001 VP/cell. These 
data suggest that higher amounts of fusion protein are produced from replicating viruses, and 
that coupling of transgene expression to replication allowed detection of replication by 
analysis of GFP.  
 
3.2 Effect of GCV on virus replication (III) 
It has been proposed that GCV might block viral proliferation and subsequent spreading of 
oncolytic viruses (Morris & Wildner 2000, Rogulski et al. 2000b, Wildner & Morris 2000, 
Nanda et al. 2001). These proposals are not surprising since the toxic form of the drug acts by 
incorporating into DNA, thus competing with endogenous DNA precursors. Thereafter, 
elongation of DNA strands is prevented and further DNA synthesis inhibited (Ilsley et al. 
1995, Haynes et al. 1996, Thust et al. 1996). 
 We evaluated the kinetics of Ad5/3-Δ24-TK-GFP in the presence of GCV. Ovarian 
cancer cells were infected with Ad5/3-Δ24-TK-GFP and GCV was added according to 
different schedules (figure 2 in III). When GCV was given 1h post-infection, practically no 
infectious particles were formed, indicating that GCV has a dramatic inhibitory effect on viral 
replication when given immediately after the virus. Such a safety switch mechanism might be 
useful if it becomes necessary to abrogate virus replication (Wildner 2003)  Administration of 
GCV 24h post-infection resulted in a 10-fold reduction in the amount of viable virus at 48h 
and 72h after infection. A plateau was reached for Ad5/3-Δ24-TK-GFP after 48h and 
therefore, it was logical that GCV added at this time-point did not decrease the number of 
infectious particles. These results are in parallel with previous studies suggesting GCV-
induced inhibition of viral replication (Morris & Wildner 2000, Rogulski et al. 2000b, 
Wildner & Morris 2000, Nanda et al. 2001). Further, our results indicate the importance of 
GCV scheduling in order to achieve a balance between a GCV-mediated decrease in 
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cytotoxicity by inhibition of viral replication and a GCV-mediated increase in cytotoxicity by 
bystander effect. 
 
3.3 Oncolytic potency in the presence of ganciclovir in vitro (III) 
To evaluate whether the TK/GCV system can improve the efficacy of oncolytic virotherapy in 
vitro, ovarian cancer cells were infected with Ad5/3-∆24-TK-GFP or Ad5/3-TK-GFP and 
exposed to GCV at 1h, 24h, 48h, 72h or 96h post-infection. MTS assay was used as an 
indicator of cell viability. On SKOV3.ip1 cells, Ad5/3-∆24-TK-GFP infection in combination 
with GCV resulted in significantly enhanced cell killing compared with virus alone in all 
analyzed treatment schedules (supplementary figure 2 in III). When GCV was given 48h after 
infection with 1 VP/cell of Ad5/3-∆24-TK-GFP, virus alone resulted in 87% cell viability, 
whereas combination treatment decreased the proportion of living cells to 10% (P<0.001)  
(figure 3a in III). SKOV3.ip1 cells are known to be sensitive to the bystander effect 
(Hakkarainen et al. 2005), which may explain why GCV increased cell killing despite 
abrogation of virus replication.  
 With Hey and OV-4 cells (figure 3b and 3c in III), replication of Ad5/3-∆24-TK-GFP was 
rapid and administration of GCV 48h post-infection did not significantly increase 
cytotoxicity. Other time-points yielded similar data. In a recent study, infection with another 
oncolytic adenovirus, Ad5-Δ24TK-GFP, resulted in enhanced cell killing of both Hey and 
OV-4 cells when combined with GCV (Hakkarainen et al. 2006).  Entry of Ad5-Δ24TK-GFP 
into target cells is dependent on CAR expression, which has been demonstrated to be low in 
Hey and OV-4 cells (Kanerva et al. 2002a). Therefore, less cells were infected by the CAR-
binding Ad5-Δ24TK-GFP, and the need for the GCV-induced bystander effect was more 
urgent. Further, expression of TK-GFP was driven by the CMV promoter placed in the 
deleted E3 region, which might not be optimal for effective replication because both deletion 
of the entire E3 and CMV-directed expression are known to reduce production of new virions 
(Suzuki et al. 2002).   
 GCV was useful in combination with replication-deficient Ad5/3-TK-GFP with all cell 
lines and schedules compared with virus alone (P<0.001 at 100 VP/cell). However, oncolytic 
virus alone led to more efficient cell killing than E1-deleted virus combined with GCV. Our 
in vitro data suggest that the utility of TK/GCV-mediated cell killing is most evident in the 
context of replication-deficient viruses. In contrast to the effect on virus replication, GCV 
timing did not influence cell killing dramatically. However, allowing the virus to replicate 
prior to GCV treatment is useful because of the inhibitory effect on replication and the 
subsequently reduced transgene production.  
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3.4 Antitumor efficacy in subcutaneous and intraperitoneal murine 
models of ovarian cancer (III) 
The antitumor efficacy of Ad5/3-Δ24-TK-GFP and feasibility of TK/GCV system was 
analyzed in human xenografts of ovarian cancer. To study whether flank tumor growth in 
nude mice might be inhibited, s.c. SKOV3-luc tumor-bearing mice were treated i.t. with two 
cycles of Ad5/3-∆24-TK-GFP or replication-deficient Ad5/3-TK-GFP, and GCV was 
administered i.p. for one week starting 48h after the last viral injections (figure 4a in III). Both 
viruses alone and together with GCV reduced tumor growth significantly compared with 
untreated animals (all P<0.006). Further, both Ad5/3-Δ24-TK-GFP alone and coupled with 
GCV were more efficient in inhibiting tumor growth than E1-deleted Ad5/3-TK-GFP with 
GCV (P<0.001). Interestingly, GCV did not provide an additional therapeutic benefit when 
combined with Ad5/3-Δ24-TK-GFP (P=0.495).  
 Therapeutic efficacy was also evaluated in an orthotopic murine model of ovarian cancer. 
SCID mice with peritoneal SKOV3-luc carcinomatosis were injected i.p. with Ad5/3-∆24-
TK-GFP or Ad5/3-TK-GFP followed by daily GCV for two weeks starting 48h after virus 
injection (figure 6a in III). The median survival of untreated mice was 32 days, and treatment 
with replication-deficient Ad5/3-TK-GFP together with GCV increased it to 36 days 
(P=0.001). Oncolytic Ad5/3-Δ24-TK-GFP alone or in combination with GCV resulted in 
median survival of 46 and 47 days, respectively, both of which were significantly improved 
compared with untreated animals (P<0.001). However, GCV did not add a significant 
survival benefit relative to Ad5/3-Δ24-TK-GFP alone (P=0.481). Again, treatment with 
Ad5/3-Δ24-TK-GFP alone led to significantly enhanced survival compared with E1-deleted 
Ad5/3-TK-GFP combined with GCV (P=0.023).  
 In summary, our in vivo data demonstrate that TK/GCV does not augment antitumor 
efficacy, as delivery of GCV failed to reduce tumor growth or increase survival compared 
with oncolytic virus alone. This data is in accordance with other studies combining oncolytic 
adenoviruses with the TK/GCV system (Morris & Wildner 2000, Rogulski et al. 2000b, 
Wildner & Morris 2000, Lambright et al. 2001, Hakkarainen et al. 2006).  High oncolytic 
potency might reduce the utility of prodrug conversion because of the strong lytic effect 
caused by virus dissemination. Prodrug conversion might also affect virus replication, which 
could work against oncolysis. Other arming approaches could therefore be more useful in the 
context of highly potent oncolytic adenoviruses (Boland et al. 2000, Erbs et al. 2000, 
Lukashev et al. 2005, Oosterhoff et al. 2005, Ramesh et al. 2006).  
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3.5 Noninvasive imaging of tumor growth and virus replication (III)  
Noninvasive imaging techniques provide a useful tool for preclinical and clinical gene therapy 
research as well as for diagnostic use (Min & Gambhir 2004). In this approach, reporter gene 
expression is monitored in living organisms, which allows more efficient utilization of 
orthotopic model systems and offers the possibility of performing repeated measurements. We 
utilized noninvasive bioluminescence and fluorescence imaging to follow tumor development 
and virus dissemination in mice. 
 Luciferase-expressing SKOV3-luc ovarian cancer cells were detected with 
bioluminescence imaging after administration of D-luciferin. The advantage of 
bioluminescence is minimal background noise, as luciferase is not a natural constituent of 
mammalian organisms (Min & Gambhir 2004). The total flux of emitted light was measured 
(figures 4b and 6b in III), and the extent of disease was visualized with pseudocolor images of 
luciferase expression (figures 7 and 9, figures 4c and 6c in III). In s.c. model, good correlation 
was seen between tumor size and photon emission data. Administration of GCV did not 
significantly affect photon flux compared with viruses alone (P=0.899 for Ad5/3-Δ24-TK-
GFP and P=0.061 for Ad5/3-TK-GFP). Results with i.p. xenografts were in accordance with 
survival data, as photon flux from mice treated with Ad5/3-Δ24-TK-GFP alone or in 
combination with GCV did not differ significantly (P=0.707). However, both treatments 
resulted in a smaller tumor load than in untreated mice (P<0.002). 
 Replication and spreading of TK-GFP expressing viruses in flank tumors were followed 
with fluorescence imaging of GFP expression (figure 8, figure 5 in III). Signals emitted from 
Ad5/3-Δ24-TK-GFP-treated tumors seemed higher than in tumors injected with Ad5/3-TK-
GFP, indicating effective replication of the virus, although differences were not statistically 
significant. Utilization of fluorescence imaging to monitor transgene expression might be 
problematic. Since mammalian tissues absorb light that is used to excite GFP, the tissues also 
fluoresce when excited at these wavelengths known to have limited penetration in mammalian 
tissues. The combination of absorption of specific signal and autofluorescence can result in a 
poor and noisy signal (Bogdanov & Weissleder 2002). This phenomenon was also evident in 
our studies, as we were unable to detect GFP at all time-points due to high background 
fluorescence levels. In addition to its therapeutic value, TK could also be used as a reporter 
gene. Radionuclide imaging with positron emission tomography (PET) or single photon 
emission tomography (SPECT) allows noninvasive detection of TK gene transfer and 
expression (Tjuvajev et al. 1996, Tjuvajev et al. 1998). 
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Figure 7. Bioluminescence imaging of luciferase-expressing ovarian cancer cells in subcutaneous model of 
ovarian cancer. Pseudocolor images of s.c. tumors in flanks of nude mice treated with two rounds of 1 x 108 VP 
Ad5/3-Δ24-TK-GFP or Ad5/3-TK-GFP i.t. on days 7-9 and 19-21. 50 mg/kg GCV was injected i.p. 48h after 
viral injections (days 11-17 and 23-29). Color scale minimum and maximum have been adjusted so that they are 
identical in each image. 
 
Figure 8. Fluorescence emitted from Ad5/3-Δ24-TK-GFP- or 
Ad5/3-TK-GFP-injected tumors on day 22. Color scale minimum 
and maximum have been adjusted so that they are identical in 
each image. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Bioluminescence imaging of luciferase-expressing ovarian cancer cells in a murine model of 
peritoneally disseminated ovarian cancer. Pseudocolor images of i.p. tumor burden in SCID mice treated with 1 
x 108 VP Ad5/3-Δ24-TK-GFP or Ad5/3-TK-GFP i.p. on day 5 followed by 50 mg/kg GCV i.p. daily for two 
weeks starting on day 7. Color scale minimum and maximum have been adjusted so that they are identical in 
each image. 
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4. Inhibition of virus replication and associated toxicity with 
pharmacological agents (IV) 
 
Oncolytic adenoviruses have been well tolerated in cancer trials at doses of up to 2 x 1013 VP 
(Nemunaitis et al. 2001a). However, most studies have been carried out with E1B-55 kD-
deleted ONYX-015, which is somewhat attenuated even in tumor cells compared with the 
Ad5 wild-type (Kirn 2001). Newer generation agents replicate similarly or even more rapidly 
than the wild-type adenovirus (Fueyo et al. 2000, Heise et al. 2000a, Kanerva et al. 2003). 
More potent oncolytic adenoviruses could mean more unwanted side-effects, especially in 
immunosuppressed patients. We hypothesized that we may be able to increase the safety of 
oncolytic adenoviruses by developing means for pharmacological intervention for reduction 
of replication, which might be useful in the event of severe side-effects in trials. 
 We evaluated the antiviral activity of the antipsychotic agent chlorpromazine and the 
natural bioflavonoid apigenin. Chlorpromazine has been used for decades in millions of 
humans and its safety and side-effect profile are well known (Lehman et al. 2004). Apigenin 
has also been studied in clinical trials, with good safety data (Nielsen et al. 1999). These 
agents possess different mechanisms of action since chlorpromazine works at the 
transductional level by inhibiting clathrin-mediated endocytosis (Wang et al. 1993), and 
apigenin blocks DNA synthesis (Sato et al. 1994, Lepley & Pelling 1997, Wang et al. 2000, 
Yin et al. 2001). 
 
4.1 Reduction of replication in normal tissues in vitro (IV) 
The in vitro replication of Ad5 wild-type adenovirus and oncolytic adenovirus Ad5/3-∆24 in 
combination with drugs was analyzed in fresh human liver explants. Wild-type virus alone 
displayed replication over 48h, and chlorpromazine reduced the titer 8-fold (P=0.0271) at the 
last time-point (figure 1a in IV). Further, lower liver aspartate transaminase (AST) levels 
measured from chlorpromazine-treated livers suggested reduced hepatocyte damage (figure 1e 
in IV). Importantly, as Ad5/3-∆24 is in development for human trials, it did not replicate 
productively in the human liver explants (figure 1b in IV). Nevertheless, even marginal 
replication was further attenuated by chlorpromazine, as evidenced by decreasing titer at later 
time-points. In nonmalignant E1-transformed 293 cells, both viruses replicated efficiently, 
and administration of chlorpromazine reduced replication up to 1960-fold (P=0.0056 for wild-
type, and P=0.0040 for Ad5/3-∆24) at 48h post-infection (figures 1c and 1d in IV).   
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4.2 Reduction of replication in cancer cells in vitro (IV) 
Next, viral replication coupled with pharmacological agents was examined in tumor cells. In 
ovarian adenocarcinoma Hey cells, apigenin reduced replication of both wild-type and Ad5/3-
∆24, with a significant difference (P=0.0156 and P=0.0478, respectively) at 72h post-
infection (figures 2a and 2b in IV). However, the effect was less pronounced in another 
ovarian cancer cell line, OV-4 (figures 2c and 2d in IV). Presumably, genetic heterogeneity 
between OV-4 and Hey resulted in variation in replication attenuation with the drugs. The 
close association of replication with cell killing was corroborated in a longitudinal assay, 
where apigenin reduced the activity of Ad5/3-∆24, resulting in increased cell viability (figure 
2e in IV). Carette et al. (2005) reported a reduction of 3 to 4 orders of magnitude in oncolytic 
adenovirus DNA copy number with apigenin treatment in a quantitative PCR assay, and also 
the expression of transgene was reduced up to 4 logs in various cancer cell lines. Of note, in 
those experiments, the apigenin concentration was 8 times higher than the concentration that 
we utilized. 
 Interestingly, although chlorpromazine inhibited viral replication in normal tissues, an 
inhibitory effect was not evident in cancer cells. Administration of apigenin, by contrast, had 
the opposite effect. This could be explained by molecular differences between normal and 
malignant cells. Hey cells are known to proliferate very rapidly and efficiently in vitro, which 
might partly explain the stronger inhibitory effect by apigenin since it arrests the cell cycle, 
thus preventing DNA synthesis.   
 
4.3 Reduction of replication and toxicity in vivo (IV) 
In a s.c. human xenograft of ovarian cancer, both apigenin and chlorpromazine were found to 
decrease the antitumor efficacy of Ad5/3-∆24 (both P<0.0001) (figure 3a in IV). This was due 
to reduced replication of the virus (figure 3b in IV). Production of new viruses was reduced 
36-fold with chlorpromazine. An 11-fold decrease was seen also with apigenin. Neither 
apigenin nor chlorpromazine resulted in therapeutic benefit by itself, although apigenin has 
been proposed to possess anticancer activity in several cancer types (Patel et al. 2007). We do 
not fully understand the reason for the discrepancy in the effect of chlorpromazine on Hey 
cells with Ad5/3-∆24 in vitro and in vivo. However, because this virus replicates very rapidly 
in vitro, the speed of replication may actually become counterproductive to packaging of 
functional virions. Theoretically, cells might be lysed before producing the maximum number 
of virions. Thus, slowing of the speed of replication may not necessarily be seen as reduction 
of in vitro virion production. Nevertheless, tumor penetration and i.t. dissemination might be 
improved by rapid replication and release, and these aspects cannot be assessed in vitro. 
58 
 
Therefore, we feel that the in vivo data gives a more complete and relevant picture of the 
actions of the drugs.  
 To assess adenovirus-associated toxicity, we utilized a murine model where peritoneally 
disseminated human ovarian cancer is first inoculated and then cured by injecting Ad5/3-∆24 
and gemcitabine, a combination that has previously resulted in toxicity and liver damage. In 
this study, mice succumbed to liver necrosis, foamy degeneration, and steatosis. Further, the 
few surviving hepatocytes displayed large nuclei (figure 4b in IV). Of note, apigenin- or 
chlorpromazine-treated mice displayed less liver damage (figure 4c and 4d in IV). When all 
evaluable livers were analyzed in a blinded manner, liver toxicity was present more often in 
the control group than in mice receiving apigenin or chlorpromazine (P=0.0213).  
 These data suggest that apigenin and chlorpromazine can reduce the replication of 
adenoviruses in vitro and in vivo, which could provide a safety switch in case of unwanted 
side-effects. Compounding the need for an antidote, virus replication may persist for weeks, 
as opposed to most conventional medicines that have short half-lives.  
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SUMMARY AND CONCLUSIONS 
 
In this study, we evaluated different approaches for improving safety and efficacy of 
oncolytic virotherapy against human ovarian adenocarcinoma.  
 We examined the antitumor efficacy of Ad5/3-Δ24, a serotype 3 receptor-targeted pRb-
p16 pathway-selective oncolytic adenovirus, in combination with conventional 
chemotherapeutic agents. We observed synergistic activity in ovarian cancer cells in vitro 
when Ad5/3-Δ24 was given with either gemcitabine or epirubicin, common second-line 
treatment options for ovarian cancer. Our results also suggest that gemcitabine decreases the 
level of Ad5/3-Δ24 replication early after infection. In murine xenografs of peritoneally 
disseminated ovarian cancer, delivery of Ad5/3-Δ24 with either gemcitabine or epirubicin 
resulted in a greater therapeutic efficacy than single agents. However, dosage and timing of 
gemcitabine treatment played a major role in defining the treatment outcome, as some mice 
with certain schedules died due to treatment-related liver damage. This was especially the 
case when Ad5/3-Δ24 was given 24h prior to gemcitabine treatment, indicating that toxicity 
might result due to chemosensitizing activity of adenoviral E1A. Importantly, administration 
of Ad5/3-Δ24 24h after gemcitabine resulted in dramatically enhanced survival, and 60% of 
mice were tumor-free at the end of the experiment. Considering the synergistic effect that 
many gene therapy approaches have with existing treatments, it is likely that the first routine 
clinical applications will be combination treatments with traditional modalities. 
 We analyzed the feasibility of the TK/GCV system in the context of infectivity-enhanced 
oncolytic adenoviruses. Infection with Ad5/3-Δ24-TK-GFP, a novel virus harboring the TK-
GFP fusion gene, resulted in complete killing of ovarian cancer cells. However, Ad5/3-Δ24-
TK-GFP replicated at slightly lower levels than control viruses, possibly due to transgene 
expression. Alternatively, the larger genome size may have slowed replication. Replication 
was associated with increased GFP expression, indicating effective production of the 
transgene. Administration of GCV immediately after Ad5/3-Δ24-TK-GFP infection caused 
almost total inhibition of DNA replication. However, oncolytic potency in vitro was enhanced 
after exposure to the GCV cell line-dependently and regardless of timing. Unfortunately, 
administration of GCV did not further improve therapeutic efficacy of this highly potent 
oncolytic agent in murine models of metastatic ovarian cancer. Finally, we utilized 
noninvasive bioluminescence and fluorescence imaging to monitor tumor development and 
virus replication in living mice.  
 As many common chemotherapeutic agents and prodrugs act through inhibition of DNA 
synthesis, optimizing treatment protocols becomes an important issue. Our results 
demonstrate that correct scheduling of the agents is required to achieve the maximum benefit 
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from both agents. The key factor appears to be a balance between a drug-induced increase in 
cell killing due to its cytotoxic mechanisms and a drug-induced reduction in cell killing due to 
inhibition of viral replication.  
 Orthotopic murine models of ovarian cancer were utilized to study the effect of dose and 
scheduling of intraperitoneally delivered Ad5/3-Δ24. Treatment outcome after administration 
of a single dose did not differ significantly from delivery of multiple rounds of Ad5/3-Δ24. 
Dose de-escalation suggested a trend towards dose-dependency since treatment with the 
highest dose resulted in the highest survival rates. However, even the lowest viral dose of 100 
VP was sufficient to increase the survival of mice significantly compared with untreated 
animals. These results are in accordance with the potent amplification of the agent. 
 Finally, we evaluated whether safety of Ad5/3-Δ24 could be improved by developing 
means for pharmacological intervention for reduction of replication, which might be useful in 
the event of severe side-effects in trials. The antiviral effect of chlorpromazine and apigenin 
was analyzed in fresh human liver samples as well as in established normal cells and cancer 
cells in vitro. Further, we utilized murine models of ovarian cancer to evaluate antitumor 
efficacy, viral replication, and liver toxicity in the presesence of drugs in vivo. Our data show 
that these agents can decrease the rate of adenoviral replication, which could provide a safety 
switch in case of treatment-associated side-effects. 
 In conclusion, we demonstrate that Ad5/3-Δ24 is a useful oncolytic agent for treatment of 
ovarian cancer either alone or in combination with conventional chemotherapeutic drugs. 
Insertion of genes encoding prodrug-converting enzymes into the genome of Ad5/3-Δ24 
might not lead to enhanced antitumor efficacy with this highly potent oncolytic virus. As a 
safety feature, viral activity can be inhibited with pharmacological substances. Clinical trials 
are however needed to confirm if these preclinical results can be translated into efficacy in 
humans. Promising safety data seen here, and in previous publications suggest that clinical 
evaluation of the agent is feasible. Importantly, Ad5/3-Δ24 is currently heading towards 
clinical trial against recurrent ovarian cancer. 
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